1
|
Abstract
The insulin-like growth factor receptor (IGF1R) pathway plays an important role in cancer progression. In breast cancer, the IGF1R pathway is linked to estrogen-dependent signaling. Regulation of IGF1R activity is complex and involves the actions of its ligands IGF1 and IGF2 and those of IGF-binding proteins (IGFBPs). Six IGFBPs are known that share the ability to form complexes with the IGFs, by which they control the bioavailability of these ligands. Besides, each of the IGFBPs have specific features. In this review, the focus lies on the biological effects and regulation of IGFBP5 in breast cancer. In breast cancer, estrogen is a critical regulator of IGFBP5 transcription. It exerts its effect through an intergenic enhancer loop that is part of the chromosomal breast cancer susceptibility region 2q35. The biological effects of IGFBP5 depend upon the cellular context. By inhibiting or promoting IGF1R signaling, IGFBP5 can either act as a tumor suppressor or promoter. Additionally, IGFBP5 possesses IGF-independent activities, which contribute to the complexity by which IGFBP5 interferes with cancer cell behavior.
Collapse
|
2
|
Zhang ZM, Min L, Jiang DL, Han ZY, Wang LH. Insulin-Like Growth Factor Binding Protein 5: an Important Regulator of Early Osteogenic Differentiation of hMSCs. Folia Biol (Praha) 2021; 67:118-125. [PMID: 35151245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Insulin-like growth factor binding protein 5 (IGFBP5) is broadly bioactive, but its role in osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (hMSCs) remains to be clarified. Here, we demonstrated that IGFBP5 expression was markedly increased during the early osteogenic differentiation of hMSCs. We then over-expressed and knocked down this gene in hMSCs and evaluated the impact of manipulation of IGFBP5 expression on osteogenic differentiation based upon functional assays, ALP staining, and expression of osteogenic markers. Together, these analyses revealed that IGFBP5 over-expression enhanced early osteogenic differentiation, as evidenced by increased ALP staining and osteogenic marker induction, whereas knocking down this gene impaired the osteogenic process. Over-expression of IGFBP5 also markedly bolstered the extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation level, while IGFBP5 knockdown suppressed this signalling activity. We additionally compared the impact of simultaneous IGFBP5 overexpression and ERK1/2 inhibitor treatment to the effect of IGFBP5 over-expression alone in these hMSCs, revealing that small molecule-mediated EKR1/2 inhibition was sufficient to impair osteogenic differentiation in the context of elevated IGFBP5 levels. These findings indicated that IGFBP5 drives the early osteogenic differentiation of hMSCs via the ERK1/2 signalling pathway. Our results offer value as a foundation for future efforts to study and treat serious bone-related diseases including osteoporosis.
Collapse
Affiliation(s)
- Z M Zhang
- Department of Critical Care Medicine, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China
| | - L Min
- Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China
| | - D L Jiang
- Department of Clinical laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China
| | - Z Y Han
- Department of Clinical laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China
| | - L H Wang
- Department of Clinical laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China
| |
Collapse
|
3
|
Nguyen XX, Sanderson M, Helke K, Feghali-Bostwick C. Phenotypic Characterization of Transgenic Mice Expressing Human IGFBP-5. Int J Mol Sci 2020; 22:ijms22010335. [PMID: 33396956 PMCID: PMC7795366 DOI: 10.3390/ijms22010335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 11/29/2020] [Accepted: 12/25/2020] [Indexed: 01/06/2023] Open
Abstract
Pulmonary fibrosis is one of the important causes of morbidity and mortality in fibroproliferative disorders such as systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). Insulin-like growth factor binding protein-5 (IGFBP-5) is a conserved member of the IGFBP family of proteins that is overexpressed in SSc and IPF lung tissues. In this study, we investigated the functional role of IGFBP-5 in the development of fibrosis in vivo using a transgenic model. We generated transgenic mice ubiquitously expressing human IGFBP-5 using CRISPR/Cas9 knock-in. Our data show that the heterozygous and homozygous mice are viable and express human IGFBP-5 (hIGFBP-5). Transgenic mice had increased expression of extracellular matrix (ECM) genes, especially Col3a1, Fn, and Lox in lung and skin tissues of mice expressing higher transgene levels. Histologic analysis of the skin tissues showed increased dermal thickness, and the lung histology showed subtle changes in the heterozygous and homozygous mice as compared with the wild-type mice. These changes were more pronounced in animals expressing higher levels of hIGFBP-5. Bleomycin increased ECM gene expression in wild-type mice and accentuated an increase in ECM gene expression in transgenic mice, suggesting that transgene expression exacerbated bleomycin-induced pulmonary fibrosis. Primary lung fibroblasts cultured from lung tissues of homozygous transgenic mice showed significant increases in ECM gene expression and protein levels, further supporting the observation that IGFBP-5 resulted in a fibrotic phenotype in fibroblasts. In summary, transgenic mice expressing human IGFBP-5 could serve as a useful animal model for examining the function of IGFBP-5 in vivo.
Collapse
Affiliation(s)
- Xinh-Xinh Nguyen
- Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA; (X.-X.N.); (M.S.)
| | - Matthew Sanderson
- Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA; (X.-X.N.); (M.S.)
| | - Kristi Helke
- Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC 29425, USA;
- Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
| | - Carol Feghali-Bostwick
- Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA; (X.-X.N.); (M.S.)
- Correspondence: ; Tel.: +1-843-876-2315
| |
Collapse
|
4
|
Jenkins EC, Brown SO, Germain D. The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning. J Mammary Gland Biol Neoplasia 2020; 25:181-189. [PMID: 32901383 DOI: 10.1007/s10911-020-09456-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/24/2020] [Accepted: 09/03/2020] [Indexed: 12/12/2022] Open
Abstract
Insulin-like growth factor (IGF) signaling and control of local bioavailability of free IGF by the IGF binding proteins (IGFBP) are important regulators of both mammary development and breast cancer. A recent genome-wide association study (GWAS) identified small nucleotide polymorphisms that reduce the expression of IGFBP-5 as a risk factor of developing breast cancer. This observation suggests that genetic alterations leading to a decreased level of IGFBP-5 may also contribute to breast cancer. In the current review, we focus on Pregnancy-Associated Plasma Protein A (PAPP-A), a protease involved in the degradation of IGFBP-5. PAPP-A is overexpressed in the majority of breast cancers but its role in cancer has only begun to be explored. More specifically, this review aims at highlighting the role of post-partum involution in the oncogenic function of PAPP-A. Notably, we summarize recent studies indicating that PAPP-A plays a role not only in the degradation of IGFBP-5 but also in the deposition of collagen and activation of the collagen receptor discoidin 2 (DDR2) during post-partum involution. Finally, considering the immunosuppressive microenvironment of post-partum involution, we also discuss the unexpected finding made in Ewing Sarcoma that PAPP-A plays a role in immune evasion. While the immunosuppressive role of PAPP-A in breast cancer remains to be determined, collectively these studies highlight the multifaced role of PAPP-A in cancer that extends well beyond its effect on IGF-signaling.
Collapse
Affiliation(s)
- Edmund Charles Jenkins
- Department of Medicine, Division of Hematology/ Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, 10029, USA
| | - Samantha O Brown
- Department of Medicine, Division of Hematology/ Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, 10029, USA
| | - Doris Germain
- Department of Medicine, Division of Hematology/ Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, 10029, USA.
| |
Collapse
|
5
|
Liu C, Li S, Noer PR, Kjaer-Sorensen K, Juhl AK, Goldstein A, Ke C, Oxvig C, Duan C. The metalloproteinase Papp-aa controls epithelial cell quiescence-proliferation transition. eLife 2020; 9:e52322. [PMID: 32293560 PMCID: PMC7185994 DOI: 10.7554/elife.52322] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 04/11/2020] [Indexed: 02/06/2023] Open
Abstract
Human patients carrying PAPP-A2 inactivating mutations have low bone mineral density. The underlying mechanisms for this reduced calcification are poorly understood. Using a zebrafish model, we report that Papp-aa regulates bone calcification by promoting Ca2+-transporting epithelial cell (ionocyte) quiescence-proliferation transition. Ionocytes, which are normally quiescent, re-enter the cell cycle under low [Ca2+] stress. Genetic deletion of Papp-aa, but not the closely related Papp-ab, abolished ionocyte proliferation and reduced calcified bone mass. Loss of Papp-aa expression or activity resulted in diminished IGF1 receptor-Akt-Tor signaling in ionocytes. Under low Ca2+ stress, Papp-aa cleaved Igfbp5a. Under normal conditions, however, Papp-aa proteinase activity was suppressed and IGFs were sequestered in the IGF/Igfbp complex. Pharmacological disruption of the IGF/Igfbp complex or adding free IGF1 activated IGF signaling and promoted ionocyte proliferation. These findings suggest that Papp-aa-mediated local Igfbp5a cleavage functions as a [Ca2+]-regulated molecular switch linking IGF signaling to bone calcification by stimulating epithelial cell quiescence-proliferation transition under low Ca2+ stress.
Collapse
Affiliation(s)
- Chengdong Liu
- Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, United States
| | - Shuang Li
- Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, United States
- College of Ocean and Earth Sciences, Xiamen University, Xiamen, China
| | - Pernille Rimmer Noer
- Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
| | | | - Anna Karina Juhl
- Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
| | - Allison Goldstein
- Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, United States
| | - Caihuan Ke
- College of Ocean and Earth Sciences, Xiamen University, Xiamen, China
| | - Claus Oxvig
- Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
| | - Cunming Duan
- Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, United States
| |
Collapse
|
6
|
Zhu D, Gu X, Lin Z, Yu D, Wang J, Li L. HASPIN is involved in the progression of gallbladder carcinoma. Exp Cell Res 2020; 390:111863. [PMID: 31987787 DOI: 10.1016/j.yexcr.2020.111863] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 01/19/2020] [Accepted: 01/22/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Gallbladder carcinoma (GBC) is a common malignant tumor of the biliary system, but the current treatment of GBC is unsatisfactory. Therefore, new treatment targets and strategies are urgently needed. METHODS The expression of HASPIN in GBC was detected by immunohistochemical staining. HASPIN knockdown cell model was constructed by lentivirus infection, and the infection efficiency of lentivirus and knockdown efficiency of shHASPIN were verified by fluorescence immunoassay, qRT-PCR and Western blot. The effects of HASPIN knockdown on cell proliferation, clone-formation ability and apoptosis were determined by MTT, clone formation assay, flow cytometry and Human Apoptosis Antibody Array in vitro. Besides, the effect of HASPIN knockdown on the growth of GBC solid tumors was demonstrated in vivo. RESULTS The expression of HASPIN in GBC was up-regulated and positively correlated with the pathological grade of GBC. ShHASPIN significantly down-regulated the mRNA and protein levels of HASPIN, suggesting that HASPIN knockdown cell model was successfully constructed in vitro. After HASPIN knockdown, the proliferation and clone-formation ability of GBC cells were observably inhibited, the apoptotic levels were markedly increased, and the expression of Caspase 3, IGFBP-5, p21 and sTNF-R1 related to apoptotic pathway was up-regulated. Furthermore, HASPIN knockdown inhibited the growth of GBC in vivo. CONCLUSION HASPIN was up-regulated in GBC and played an important role in promoting the progress of GBC.
Collapse
MESH Headings
- Aged
- Animals
- Apoptosis
- Carcinoma/genetics
- Carcinoma/metabolism
- Carcinoma/pathology
- Carcinoma/therapy
- Caspase 3/genetics
- Caspase 3/metabolism
- Cell Line, Tumor
- Cell Proliferation
- Clone Cells
- Cyclin-Dependent Kinase Inhibitor p21/genetics
- Cyclin-Dependent Kinase Inhibitor p21/metabolism
- Female
- Gallbladder Neoplasms/genetics
- Gallbladder Neoplasms/metabolism
- Gallbladder Neoplasms/pathology
- Gallbladder Neoplasms/therapy
- Gene Expression Regulation, Neoplastic
- Humans
- Insulin-Like Growth Factor Binding Protein 5/genetics
- Insulin-Like Growth Factor Binding Protein 5/metabolism
- Intracellular Signaling Peptides and Proteins/antagonists & inhibitors
- Intracellular Signaling Peptides and Proteins/genetics
- Intracellular Signaling Peptides and Proteins/metabolism
- Male
- Mice
- Mice, Nude
- Middle Aged
- Protein Array Analysis
- Protein Serine-Threonine Kinases/antagonists & inhibitors
- Protein Serine-Threonine Kinases/genetics
- Protein Serine-Threonine Kinases/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Small Interfering/genetics
- RNA, Small Interfering/metabolism
- Receptors, Tumor Necrosis Factor, Type I/genetics
- Receptors, Tumor Necrosis Factor, Type I/metabolism
- Signal Transduction
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Dawei Zhu
- Department of Gynaecology and Obstetrics, Daping Hospital, Army Medical University, China
| | - Xing Gu
- Department of Gynaecology and Obstetrics, Daping Hospital, Army Medical University, China
| | - Zhenyu Lin
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Dandan Yu
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Jing Wang
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
| | - Li Li
- Department of Gynaecology and Obstetrics, Daping Hospital, Army Medical University, China.
| |
Collapse
|
7
|
DiPrisco B, Kumar A, Kalra B, Savjani GV, Michael Z, Farr O, Papathanasiou AE, Christou H, Mantzoros C. Placental proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and -5), and IGF-I and IGF-II: Levels in umbilical cord blood and associations with birth weight and length. Metabolism 2019; 100:153959. [PMID: 31401027 DOI: 10.1016/j.metabol.2019.153959] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 07/02/2019] [Accepted: 08/06/2019] [Indexed: 11/20/2022]
Abstract
BACKGROUND A newborn's birth weight for gestational age provides important insights into his or her fetal growth and well-being. While the underlying mechanisms regulating fetal growth remain to be fully elucidated, the IGF axis plays an important role. Some components of this axis have been well-characterized in umbilical cord blood, but others have not yet been studied. We measured the proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and -5), and the established molecules IGF-I and -II in umbilical cord blood to better characterize the IGF axis in relation to birth weight and length. METHODS We performed a case-control study of 180 neonates born at a tertiary teaching hospital in Boston. To maximize power, infants were recruited in a 1:3:1 ratio with 37 SGA, 111 AGA, and 37 LGA infants matched by gestational age, sex, and delivery mode. IGF-I, IGF-II, IGFBP-4, IGFBP-5, PAPP-A, and PAPP-A2 were measured in umbilical cord blood by ELISA. Associations between birth weight and birth length Z-scores and the Z-scores of the above molecules were analyzed using linear regression models and analysis of covariance. RESULTS Birth weight and length Z-scores were positively associated with Z-scores of IGF-I, IGF-II, total IGFBP-4, and IGFBP-5, with IGF-I having the strongest association. Birth weight and length Z-scores were negatively associated with Z-scores of intact IGFBP-4, PAPP-A, and PAPP-A2 levels. CONCLUSIONS We confirm previous findings of significant associations between the IGFs in cord blood and newborn size and for the first time show positive associations between cord blood total IGFBP-4 and -5 and birth weight and a negative association between intact IGFBP-4 and birth weight. We also show for the first time a reciprocal relationship between cord blood levels of PAPP-A and PAPP-A2 and newborn size. The implications of these findings need to be further examined in large longitudinal studies and likely have diagnostic and therapeutic potential.
Collapse
Affiliation(s)
- Bridget DiPrisco
- Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
| | | | | | | | - Zoe Michael
- Department of Pediatric Newborn Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Olivia Farr
- Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | | | - Helen Christou
- Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Newborn Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Christos Mantzoros
- Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
8
|
Buchman AS, Yu L, Petyuk VA, Gaiteri C, Tasaki S, Blizinsky KD, Schneider JA, De Jager PL, Bennett DA. Cognition may link cortical IGFBP5 levels with motor function in older adults. PLoS One 2019; 14:e0220968. [PMID: 31404102 PMCID: PMC6690580 DOI: 10.1371/journal.pone.0220968] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Accepted: 07/26/2019] [Indexed: 12/21/2022] Open
Abstract
Alzheimer's disease and related disorders (ADRD) may manifest cognitive and non-cognitive phenotypes including motor impairment, suggesting a shared underlying biology. We tested the hypothesis that five cortical proteins identified from a gene network that drives AD and cognitive phenotypes are also related to motor function in the same individuals. We examined 1208 brains of older adults with motor and cognitive assessments prior to death. Cortical proteins were quantified with SRM proteomics and we collected indices of AD and other related pathologies. A higher level of IGFBP5 was associated with poorer motor function proximate to death but AK4, HSPB2, ITPK1 and PLXNB1 were unrelated to motor function. The association of IGFBP5 with motor function was unrelated to the presence of indices of brain pathologies. In contrast, the addition of a term for cognition attenuated the association of IGFBP5 with motor function by about 90% and they were no longer related. These data lend support for the idea that unidentified cortical proteins like IGFBP5, which may not manifest a known pathologic footprint, may contribute to motor and cognitive function in older adults.
Collapse
Affiliation(s)
- Aron S. Buchman
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
| | - Lei Yu
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
| | - Vladislav A. Petyuk
- Pacific Northwest National Laboratory, Richland, Washington, United States of America
| | - Chris Gaiteri
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
| | - Shinya Tasaki
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
| | - Katherine D. Blizinsky
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Julie A. Schneider
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, Illinois, United States of America
| | - Philip L. De Jager
- Department of Neurology, Center for Translational & Computational Neuroimmunology, Columbia University Medical Center, New York, New York, United States of America
- Cell Circuits Program, Broad Institute, Cambridge, Massachusetts, United States of America
| | - David A. Bennett
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America
| |
Collapse
|
9
|
Abstract
Insulin-like growth factor-binding protein (IGFBP)-5 is a secreted protein that binds to IGFs and modulates IGF actions, as well as regulates cell proliferation, migration, and apoptosis independent of IGF. Proper cellular localization is critical for the effective function of most signaling molecules. In previous studies, we have shown that the nuclear IGFBP-5 comes from ER-cytosol retro-translocation. In this study, we further investigated the pathway mediating IGFBP-5 nuclear import after it retro-translocation. Importin-α5 was identified as an IGFBP-5-interacting protein with a yeast two-hybrid system, and its interaction with IGFBP-5 was further confirmed by GST pull down and co-immunoprecipitation. Binding affinity of IGFBP-5 and importins were determined by surface plasmon resonance (IGFBP-5/importin-β: KD=2.44e-7, IGFBP-5/importin-α5: KD=3.4e-7). Blocking the importin-α5/importin-β nuclear import pathway using SiRNA or dominant negative impotin-β dramatically inhibited IGFBP-5-EGFP nuclear import, though importin-α5 overexpress does not affect IGFBP-5 nuclear import. Furthermore, nuclear IGFBP-5 was quantified using luciferase report assay. When deleted the IGFBP-5 nuclear localization sequence (NLS), IGFBP-5ΔNLS loss the ability to translocate into the nucleus and accumulation of IGFBP-5ΔNLS was visualized in the cytosol. Altogether, our findings provide a substantially evidence showed that the IGFBP-5 nuclear import is mediated by importin-α/importin-β complex, and NLS is critical domain in IGFBP-5 nuclear translocation.
Collapse
Affiliation(s)
- Min Sun
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
| | - Juan Long
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
| | - Yuxin Yi
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
| | - Wei Xia
- Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
10
|
Pan J, Li K, Huang W, Zhang X. MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling. PLoS One 2017; 12:e0186245. [PMID: 29016699 PMCID: PMC5634643 DOI: 10.1371/journal.pone.0186245] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2017] [Accepted: 09/27/2017] [Indexed: 12/28/2022] Open
Abstract
Abnormal proliferation of vascular smooth muscle cells (VSMCs) contributes to the development of cardiovascular diseases. Studies have shown the great impact of microRNAs (miRNAs) on the cell proliferation of VSMCs. This study examined the effects of miR-137 on the cell proliferation and migration of VSMCs and also explored the underlying molecular mechanisms. The mRNA and protein expression levels were determined by qRT-PCR and western blot assays, respectively. The CCK-8 assay, wound healing assay and transwell migration assay were performed to measure cell proliferation and migration of VSMCs. The miR-137-targeted 3’untranslated region of insulin-like growth factor-binding protein-5 (IGFBP-5) was confirmed by luciferase reporter assay. Platelet-derived growth factor-bb (PDGF-bb) treatment enhanced cell proliferation and suppressed the expression of miR-137 in VSMCs. The gain-of-function and loss-of-function assays showed that overexpression of miR-137 suppressed the cell proliferation and migration, and also inhibited the expression of matrix genes of VSMCs; down-regulation of miR-137 had the opposite effects on VSMCs. Bioinformatics analysis and luciferase report assay results showed that IGFBP-5 was a direct target of miR-137, and miR-137 overexpression suppressed the IGFBP-5 expression and down-regulation of miR-137 increased the IGFBP-5 expression in VSMCs. PDGF-bb treatment also increased the IGFBP-5 mRNA expression. In addition, enforced expression of IGFBP-5 reversed the inhibitory effects of miR-137 on cell proliferation and migration of VSMCs. More importantly, overexpression of miR-137 also suppressed the activity of mTOR/STAT3 signaling in VSMCs. Taken together, the results suggest that miR-137 may suppress cell proliferation and migration of VSMCs via targeting IGFBP-5 and modulating mTOR/STAT3 signaling pathway.
Collapse
Affiliation(s)
- Jin Pan
- Clinical Medical College, Xi'an Medical University, Xi'an City, Shaanxi Province, China
- * E-mail:
| | - Kai Li
- Department of Cardiology, the First Affiliated Hospital of Xi'an Medical University, Xi'an City, Shaanxi Province, China
| | - Wei Huang
- Clinical Medical College, Xi'an Medical University, Xi'an City, Shaanxi Province, China
| | - Xiaoqing Zhang
- Clinical Medical College, Xi'an Medical University, Xi'an City, Shaanxi Province, China
| |
Collapse
|
11
|
Garg M, Kanojia D, Mayakonda A, Said JW, Doan NB, Chien W, Ganesan TS, Huey LSC, Venkatachalam N, Baloglu E, Shacham S, Kauffman M, Koeffler HP. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget 2017; 8:7521-7532. [PMID: 27893412 PMCID: PMC5352339 DOI: 10.18632/oncotarget.13485] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 11/09/2016] [Indexed: 02/07/2023] Open
Abstract
Exportin-1 mediates nuclear export of multiple tumor suppressor and growth regulatory proteins. Aberrant expression of exportin-1 is noted in human malignancies, resulting in cytoplasmic mislocalization of its target proteins. We investigated the efficacy of selinexor against liposarcoma cells both in vitro and in vivo. Exportin-1 was highly expressed in liposarcoma samples and cell lines as determined by immunohistochemistry, western blot, and immunofluorescence assay. Knockdown of endogenous exportin-1 inhibited proliferation of liposarcoma cells. Selinexor also significantly decreased cell proliferation as well as induced cell cycle arrest and apoptosis of liposarcoma cells. The drug also significantly decreased tumor volumes and weights of liposarcoma xenografts. Importantly, selinexor inhibited insulin-like growth factor 1 (IGF1) activation of IGF-1R/AKT pathway through upregulation of insulin-like growth factor binding protein 5 (IGFBP5). Further, overexpression and knockdown experiments showed that IGFBP5 acts as a tumor suppressor and its expression was restored upon selinexor treatment of liposarcoma cells. Selinexor decreased aurora kinase A and B levels in these cells and inhibitors of these kinases suppressed the growth of the liposarcoma cells. Overall, our study showed that selinexor treatment restored tumor suppressive function of IGFBP5 and inhibited aurora kinase A and B in liposarcoma cells supporting the usefulness of selinexor as a potential therapeutic strategy for the treatment of this cancer.
Collapse
Affiliation(s)
- Manoj Garg
- Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore
- Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar Chennai, India
| | - Deepika Kanojia
- Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore
| | - Anand Mayakonda
- Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore
| | - Jonathan W Said
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
| | - Ngan B Doan
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
| | - Wenwen Chien
- Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore
| | - Trivadi S Ganesan
- Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar Chennai, India
| | | | | | | | | | | | - H. Phillip Koeffler
- Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore
- Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California Los Angeles, School of Medicine, Los Angeles, CA, USA
- National University Cancer Institute, National University Hospital, Singapore, Singapore
| |
Collapse
|
12
|
Azizi S, Nematollahi MA, Mojazi Amiri B, Vélez EJ, Salmerón C, Chan SJ, Navarro I, Capilla E, Gutiérrez J. IGF-I and IGF-II effects on local IGF system and signaling pathways in gilthead sea bream (Sparus aurata) cultured myocytes. Gen Comp Endocrinol 2016; 232:7-16. [PMID: 26602376 DOI: 10.1016/j.ygcen.2015.11.011] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 11/13/2015] [Accepted: 11/17/2015] [Indexed: 12/22/2022]
Abstract
The insulin-like growth factors (IGFs) have a fundamental role in a vast range of functions acting through a tyrosine-kinase receptor (IGF-IR). IGFs in muscle can affect the expression of components of the local IGF system, myogenic regulatory factors (MRFs), proliferating (proliferating cell nuclear antigen, PCNA) or differentiating molecules (myosin heavy chain, MHC) and, lead to the activation of different signaling pathways. The response of all these genes to IGFs incubation at two different times in day 4 cultured myocytes of gilthead sea bream was analyzed. Both IGFs increased the expression of IGF-I and IGFBP-5, but showed different effects on the receptors, with IGF-I suppressing the expression of both isoforms (IGF-IRa and IGF-IRb) and IGF-II up-regulating only IGF-IRb. Moreover, the protein levels of PCNA and target of rapamycin (TOR) increased after IGF-II incubation, although a decline in Myf5 and a rise in MHC gene expression was caused by IGF-I. Taken together, these results provide evidence for the importance of IGFs on controlling muscle development and growth in gilthead sea bream and suggest that each IGF may be preferentially acting through a specific IGF-IR. Moreover, the data support the hypothesis that IGF-II has a more important role during proliferation, whereas IGF-I seems to be relevant for the differentiation phase of myogenesis.
Collapse
Affiliation(s)
- Sheida Azizi
- Department of Fisheries Sciences, Faculty of Natural Resources, University of Tehran, Karaj, Iran; Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Mohammad Ali Nematollahi
- Department of Fisheries Sciences, Faculty of Natural Resources, University of Tehran, Karaj, Iran.
| | - Bagher Mojazi Amiri
- Department of Fisheries Sciences, Faculty of Natural Resources, University of Tehran, Karaj, Iran
| | - Emilio J Vélez
- Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Cristina Salmerón
- Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Shu Jin Chan
- Departments of Biochemistry, and Molecular Biology and Medicine, The Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA
| | - Isabel Navarro
- Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Encarnación Capilla
- Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Joaquim Gutiérrez
- Departament de Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain.
| |
Collapse
|
13
|
Tripathy S, Asaithambi K, P J, R M. Analysis of 17β-estradiol (E2) role in the regulation of corpus luteum function in pregnant rats: Involvement of IGFBP5 in the E2-mediated actions. Reprod Biol Endocrinol 2016; 14:19. [PMID: 27072650 PMCID: PMC4830059 DOI: 10.1186/s12958-016-0153-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Accepted: 03/25/2016] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND In several species, considerably higher levels of estradiol-17 (E2) are synthesized in the CL. E2 has been suggested to participate in the regulation of luteal steroidogenesis and luteal cell morphology. In pregnant rats, several experiments have been carried out to examine the effects of inhibition of luteal E2 synthesis on CL structure and function. METHODS During days 12-15 of pregnancy in rats, luteal E2 was inhibited by way of daily oral administration of anastrozole (AI), a selective non-steroidal aromatase inhibitor, and experiments were also performed with E2 replacement i.e. AI+ E2 treatments. Luteal tissues from different treatment groups were subjected to microarray analysis and the differentially expressed genes in E2 treated group were further examined for expression of specific E2 responsive genes. Additional experiments were carried out employing recombinant growth hormone preparation and flutamide, an androgen receptor antagonist, to further address the specificity of E2 effects on the luteal tissue. RESULTS Microarray analysis of CL collected on day 16 of pregnancy post AI and AI+E2 treatments showed significantly lowered cyp19a1 expression, E2 levels and differential expression of a number of genes, and several of them were reversed in E2 replacement studies. From the differentially expressed genes, a number of E2 responsive genes were identified. In CL of AI pregnant rats, non-significant increase in expression of igf1, significant increase in igbp5, igf1r and decrease in expression of Erα were observed. In liver of AI treated rats, igf1 expression did not increase, but GH treatment significantly increased expression that was further increased with AI treatment. In CL of GH and AI+GH treated rats, expression of igfbp5 was higher. Administration of flutamide during days 12-15 of pregnancy resulted in non-significant increase in igfbp5 expression, however, combination of flutamide+AI treatments caused increased protein expression. Expression of few of the molecules in PI3K/Akt kinase pathway in different treatments was determined. CONCLUSIONS The results suggest a role for E2 in the regulation of luteal steroidogenesis, morphology and proliferation. igfbp5 was identified as one the E2 responsive genes with important role in the mediation of E2 actions such as E2-induced phosphorylation of PI3K/Akt kinase pathway.
Collapse
Affiliation(s)
- Sudeshna Tripathy
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012 India
| | - Killivalavan Asaithambi
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012 India
| | - Jayaram P
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012 India
| | - Medhamurthy R
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012 India
| |
Collapse
|
14
|
Soriano‐Arroquia A, McCormick R, Molloy AP, McArdle A, Goljanek‐Whysall K. Age-related changes in miR-143-3p:Igfbp5 interactions affect muscle regeneration. Aging Cell 2016; 15:361-9. [PMID: 26762731 PMCID: PMC4783349 DOI: 10.1111/acel.12442] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2015] [Indexed: 12/27/2022] Open
Abstract
A common characteristic of aging is defective regeneration of skeletal muscle. The molecular pathways underlying age-related decline in muscle regenerative potential remain elusive. microRNAs are novel gene regulators controlling development and homeostasis and the regeneration of most tissues, including skeletal muscle. Here, we use satellite cells and primary myoblasts from mice and humans and an in vitro regeneration model, to show that disrupted expression of microRNA-143-3p and its target gene, Igfbp5, plays an important role in muscle regeneration in vitro. We identified miR-143 as a regulator of the insulin growth factor-binding protein 5 (Igfbp5) in primary myoblasts and show that the expression of miR-143 and its target gene is disrupted in satellite cells from old mice. Moreover, we show that downregulation of miR-143 during aging may act as a compensatory mechanism aiming at improving myogenesis efficiency; however, concomitant upregulation of miR-143 target gene, Igfbp5, is associated with increased cell senescence, thus affecting myogenesis. Our data demonstrate that dysregulation of miR-143-3p:Igfbp5 interactions in satellite cells with age may be responsible for age-related changes in satellite cell function.
Collapse
Affiliation(s)
- Ana Soriano‐Arroquia
- Institute of Ageing and Chronic DiseaseUniversity of Liverpool6 West Derby StreetLiverpoolL7 8TXUK
| | - Rachel McCormick
- Institute of Ageing and Chronic DiseaseUniversity of Liverpool6 West Derby StreetLiverpoolL7 8TXUK
| | | | - Anne McArdle
- Institute of Ageing and Chronic DiseaseUniversity of Liverpool6 West Derby StreetLiverpoolL7 8TXUK
| | | |
Collapse
|
15
|
Rojas-Rodriguez R, Lifshitz LM, Bellve KD, Min SY, Pires J, Leung K, Boeras C, Sert A, Draper JT, Corvera S, Moore Simas TA. Human adipose tissue expansion in pregnancy is impaired in gestational diabetes mellitus. Diabetologia 2015; 58:2106-14. [PMID: 26067361 PMCID: PMC4526585 DOI: 10.1007/s00125-015-3662-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 05/19/2015] [Indexed: 12/26/2022]
Abstract
AIMS/HYPOTHESIS During pregnancy, adipose tissue (AT) must expand to support the growing fetus and the future nutritional needs of the offspring. Limited expandability of AT is associated with insulin resistance, attributed to ectopic lipid deposition. This study aimed to investigate human AT expandability during pregnancy and its role in the pathogenesis of gestational diabetes mellitus (GDM). METHODS This cross-sectional study of omental (OM) and subcutaneous (SQ) AT collected at Caesarean delivery included 11 pregnant and three non-pregnant women with normal glucose tolerance (NGT), five with GDM, three with type 2 diabetes mellitus. Adipocyte size, capillary density, collagen content and capillary growth were measured. Affymetrix arrays and real-time PCR studies of gene expression were performed. RESULTS Mean OM adipocyte size was greater in women with GDM than in those with NGT (p = 0.004). Mean OM and SQ capillary density was lower in GDM compared with NGT (p = 0.015). Capillary growth did not differ significantly between groups. The most differentially expressed AT transcript when comparing non-pregnant and pregnant women corresponded to the IGF binding protein (IGFBP)-5, the expression levels of which was found by subsequent quantitative real-time PCR to be lower in women with GDM vs women with NGT (p < 0.0001). CONCLUSIONS/INTERPRETATION The relative OM adipocyte hypertrophy and decreased OM and SQ capillary density are consistent with impaired AT expandability in GDM. The induction of adipose tissue IGFBP5 in pregnancy and its decrease in GDM point to the importance of the IGF-1 signalling pathway in AT expansion in pregnancy and GDM susceptibility.
Collapse
Affiliation(s)
- Raziel Rojas-Rodriguez
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605 USA
- Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA USA
| | - Lawrence M. Lifshitz
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605 USA
- Biomedical Imaging Group, University of Massachusetts Medical School, Worcester, MA USA
| | - Karl D. Bellve
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605 USA
- Biomedical Imaging Group, University of Massachusetts Medical School, Worcester, MA USA
| | - So Yun Min
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605 USA
- Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA USA
| | - Jacqueline Pires
- School of Medicine, University of Massachusetts Medical School, Worcester, MA USA
- Clinical Translational Research Pathway, University of Massachusetts Medical School, Worcester, MA USA
| | - Katherine Leung
- Department of Obstetrics & Gynecology, Division of Research, University of Massachusetts Medical School/UMass Memorial Health Care, Memorial Campus - 119 Belmont Street, Worcester, MA 01605 USA
| | - Crina Boeras
- Department of Obstetrics & Gynecology, Division of Research, University of Massachusetts Medical School/UMass Memorial Health Care, Memorial Campus - 119 Belmont Street, Worcester, MA 01605 USA
| | - Aylin Sert
- School of Medicine, University of Massachusetts Medical School, Worcester, MA USA
- Department of Obstetrics & Gynecology, Division of Research, University of Massachusetts Medical School/UMass Memorial Health Care, Memorial Campus - 119 Belmont Street, Worcester, MA 01605 USA
| | - Jacqueline T. Draper
- School of Medicine, University of Massachusetts Medical School, Worcester, MA USA
| | - Silvia Corvera
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605 USA
| | - Tiffany A. Moore Simas
- Department of Obstetrics & Gynecology, Division of Research, University of Massachusetts Medical School/UMass Memorial Health Care, Memorial Campus - 119 Belmont Street, Worcester, MA 01605 USA
- Department of Pediatrics, University of Massachusetts Medical School/UMass Memorial Health Care, Worcester, MA USA
| |
Collapse
|
16
|
Cleveland BM, Weber GM. Effects of sex steroids on expression of genes regulating growth-related mechanisms in rainbow trout (Oncorhynchus mykiss). Gen Comp Endocrinol 2015; 216:103-15. [PMID: 25482545 DOI: 10.1016/j.ygcen.2014.11.018] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Revised: 11/12/2014] [Accepted: 11/24/2014] [Indexed: 12/17/2022]
Abstract
Effects of a single injection of 17β-estradiol (E2), testosterone (T), or 5β-dihydrotestosterone (DHT) on expression of genes central to the growth hormone (GH)/insulin-like growth factor (IGF) axis, muscle-regulatory factors, transforming growth factor-beta (TGFβ) superfamily signaling cascade, and estrogen receptors were determined in rainbow trout (Oncorhynchus mykiss) liver and white muscle tissue. In liver in addition to regulating GH sensitivity and IGF production, sex steroids also affected expression of IGF binding proteins, as E2, T, and DHT increased expression of igfbp2b and E2 also increased expression of igfbp2 and igfbp4. Regulation of this system also occurred in white muscle in which E2 increased expression of igf1, igf2, and igfbp5b1, suggesting anabolic capacity may be maintained in white muscle in the presence of E2. In contrast, DHT decreased expression of igfbp5b1. DHT and T decreased expression of myogenin, while other muscle regulatory factors were either not affected or responded similarly for all steroid treatments. Genes within the TGFβ superfamily signaling cascade responded to steroid treatment in both liver and muscle, suggesting a regulatory role for sex steroids in the ability to transmit signals initiated by TGFβ superfamily ligands, with a greater number of genes responding in liver than in muscle. Estrogen receptors were also regulated by sex steroids, with era1 expression increasing for all treatments in muscle, but only E2- and T-treatment in liver. E2 reduced expression of erb2 in liver. Collectively, these data identify how physiological mechanisms are regulated by sex steroids in a manner that promotes the disparate effects of androgens and estrogens on growth in salmonids.
Collapse
Affiliation(s)
- Beth M Cleveland
- National Center for Cool and Cold Water Aquaculture, USDA/ARS, 11861 Leetown Rd, Kearneysville, WV 25427, USA.
| | - Gregory M Weber
- National Center for Cool and Cold Water Aquaculture, USDA/ARS, 11861 Leetown Rd, Kearneysville, WV 25427, USA
| |
Collapse
|
17
|
Won CH, Jeong YM, Kang S, Koo TS, Park SH, Park KY, Sung YK, Sung JH. Hair-growth-promoting effect of conditioned medium of high integrin α6 and low CD 71 (α6bri/CD71dim) positive keratinocyte cells. Int J Mol Sci 2015; 16:4379-91. [PMID: 25706512 PMCID: PMC4394426 DOI: 10.3390/ijms16034379] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 02/06/2015] [Accepted: 02/11/2015] [Indexed: 11/16/2022] Open
Abstract
Keratinocyte stem/progenitor cells (KSCs) reside in the bulge region of the hair follicles and may be involved in hair growth. Hair follicle dermal papilla cells (HFDPCs) and outer root sheath (ORS) cells were treated with conditioned medium (CM) of KSCs. Moreover, the effects of KSC-CM on hair growth were examined ex vivo and in vivo. A human growth factor chip array and RT-PCR were employed to identify enriched proteins in KSC-CM as compared with CM from keratinocytes. KSC-CM significantly increased the proliferation of HFDPCs and ORS cells, and increased the S-phase of the cell cycle in HFDPCs. KSC-CM led to the phosphorylation of ATK and ERK1/2 in both cell types. After subcutaneous injection of KSC-CM in C3H/HeN mice, a significant increase in hair growth and increased proliferation of hair matrix keratinocytes ex vivo was observed. We identified six proteins enriched in KSC-CM (amphiregulin, insulin-like growth factor binding protein-2, insulin-like growth factor binding protein-5, granulocyte macrophage-colony stimulating factor, Platelet-derived growth factor-AA, and vascular endothelial growth factor). A growth-factor cocktail that contains these six recombinant growth factors significantly increased the proliferation of HFDPCs and ORS cells and enhanced the hair growth of mouse models. These results collectively indicate that KSC-CM has the potential to increase hair growth via the proliferative capacity of HFDPCs and ORS cells.
Collapse
Affiliation(s)
- Chong Hyun Won
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea.
| | - Yun-Mi Jeong
- Department of Applied Bioscience, CHA University, Seoul 135-081, Korea.
| | - Sangjin Kang
- Department of Applied Bioscience, CHA University, Seoul 135-081, Korea.
| | - Tae-Sung Koo
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 305-764, Korea.
| | - So-Hyun Park
- Coway Cosmetics R&D Center, Seoul 153-792, Korea.
| | - Ki-Young Park
- Asan Institute for Life Sciences, Seoul 138-736, Korea.
| | - Young-Kwan Sung
- Department of Immunology, School of Medicine, Kyungpook National University, Daegu 700-422, Korea.
| | - Jong-Hyuk Sung
- College of Pharmacy, Yonsei University, Incheon 406-840, Korea.
| |
Collapse
|
18
|
Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal·lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van’t Veer LJ, Th Rutgers EJ, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Zamora MP, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, TEO SH, YIP CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 2014; 4:4999. [PMID: 25248036 PMCID: PMC4321900 DOI: 10.1038/ncomms5999] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Accepted: 08/14/2014] [Indexed: 02/07/2023] Open
Abstract
GWAS have identified a breast cancer susceptibility locus on 2q35. Here we report the fine mapping of this locus using data from 101,943 subjects from 50 case-control studies. We genotype 276 SNPs using the 'iCOGS' genotyping array and impute genotypes for a further 1,284 using 1000 Genomes Project data. All but two, strongly correlated SNPs (rs4442975 G/T and rs6721996 G/A) are excluded as candidate causal variants at odds against >100:1. The best functional candidate, rs4442975, is associated with oestrogen receptor positive (ER+) disease with an odds ratio (OR) in Europeans of 0.85 (95% confidence interval=0.84-0.87; P=1.7 × 10(-43)) per t-allele. This SNP flanks a transcriptional enhancer that physically interacts with the promoter of IGFBP5 (encoding insulin-like growth factor-binding protein 5) and displays allele-specific gene expression, FOXA1 binding and chromatin looping. Evidence suggests that the g-allele confers increased breast cancer susceptibility through relative downregulation of IGFBP5, a gene with known roles in breast cell biology.
Collapse
Affiliation(s)
- Maya Ghoussaini
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Stacey L. Edwards
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Kyriaki Michailidou
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Silje Nord
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
| | - Richard Cowper-Sal·lari
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
| | - Kinjal Desai
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
- Geisel School of Medicine, Dartmouth College,
Hanover, New Hampshire
03755, USA
| | - Siddhartha Kar
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Kristine M. Hillman
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Susanne Kaufmann
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Dylan M. Glubb
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Jonathan Beesley
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Joe Dennis
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Manjeet K. Bolla
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Qin Wang
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Ed Dicks
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Qi Guo
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Marjanka K. Schmidt
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Mitul Shah
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Robert Luben
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Judith Brown
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Hatef Darabi
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Daniel Klevebring
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Stig E. Bojesen
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
- Faculty of Health and Medical Sciences, University of
Copenhagen, 2200
Copenhagen, Denmark
| | - Børge G. Nordestgaard
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
- Faculty of Health and Medical Sciences, University of
Copenhagen, 2200
Copenhagen, Denmark
| | - Sune F. Nielsen
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
| | - Henrik Flyger
- Department of Breast Surgery, Herlev Hospital, Copenhagen
University Hospital, 2730
Herlev, Copenhagen, Denmark
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Oncology,
University of Leuven, 3000
Leuven, Belgium
- Vesalius Research Center (VRC), VIB, 3000
Leuven, Belgium
| | - Bernard Thienpont
- Vesalius Research Center (VRC), VIB, 3000
Leuven, Belgium
- Vesalius Research Center, University of Leuven,
3000
Leuven, Belgium
| | - Patrick Neven
- Department of Oncology, University of Leuven,
3000
Leuven, Belgium
- Multidisciplinary Breast Center, Department of General Medical
Oncology, University Hospitals Leuven, 3000
Leuven, Belgium
| | - Hans Wildiers
- Department of Oncology, University of Leuven,
3000
Leuven, Belgium
- Multidisciplinary Breast Center, Department of General Medical
Oncology, University Hospitals Leuven, 3000
Leuven, Belgium
| | - Annegien Broeks
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Laura J. Van’t Veer
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Emiel J. Th Rutgers
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Fergus J. Couch
- Department of Laboratory Medicine and Pathology, Mayo
Clinic, Rochester, Minnesota
55905, USA
| | - Janet E. Olson
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Emily Hallberg
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Celine Vachon
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Anja Rudolph
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Petra Seibold
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Dieter Flesch-Janys
- Department of Cancer Epidemiology/Clinical Cancer Registry and
Institute for Medical Biometrics and Epidemiology, University Clinic
Hamburg-Eppendorf, 20246
Hamburg, Germany
| | - Julian Peto
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Isabel dos-Santos-Silva
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Lorna Gibson
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University
Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Taru A. Muranen
- Department of Obstetrics and Gynecology, Helsinki University
Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Kristiina Aittomäki
- Department of Clinical Genetics, University of Helsinki,
Helsinki University Central Hospital, Helsinki,
FI-00029
HUS, Finland
| | - Carl Blomqvist
- Department of Oncology, University of Helsinki, Helsinki
University Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Jingmei Li
- Human Genetics Division, Genome Institute of Singapore,
Singapore
138672, Singapore
| | - Jianjun Liu
- Human Genetics Division, Genome Institute of Singapore,
Singapore
138672, Singapore
| | - Keith Humphreys
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Daehee Kang
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
- Department of Preventive Medicine, Seoul National University
College of Medicine, Seoul
110-799, Korea
| | - Ji-Yeob Choi
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
| | - Sue K. Park
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
- Department of Preventive Medicine, Seoul National University
College of Medicine, Seoul
110-799, Korea
| | - Dong-Young Noh
- Department of Surgery, Seoul National University College of
Medicine, Seoul
110-799, Korea
| | - Keitaro Matsuo
- Department of Preventive Medicine, Kyushu University Faculty of
Medical Sciences, Fukuoka
812-8582, Japan
| | - Hidemi Ito
- Division of Epidemiology and Prevention, Aichi Cancer Center
Research Institute, Nagoya, Aichi
464-8681, Japan
| | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center
Hospital, Nagoya
484-8681, Japan
| | - Yasushi Yatabe
- Department of Pathology and Molecular Diagnostics, Aichi Cancer
Center Hospital, Nagoya
484-8681, Japan
| | - Pascal Guénel
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Thérèse Truong
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Florence Menegaux
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Marie Sanchez
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Barbara Burwinkel
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- Molecular Epidemiology Group, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Frederik Marme
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- National Center for Tumor Diseases, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Andreas Schneeweiss
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- National Center for Tumor Diseases, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Christof Sohn
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Anna H. Wu
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Chiu-chen Tseng
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - David Van Den Berg
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Daniel O. Stram
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Javier Benitez
- Centro de Investigación en Red de Enfermedades Raras
(CIBERER), 46010
Valencia, Spain
- Human Genetics Group, Human Cancer Genetics Program, Spanish
National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - M. Pilar Zamora
- Servicio de Oncología Médica, Hospital
Universitario La Paz, 28046
Madrid, Spain
| | | | - Primitiva Menéndez
- Servicio de Anatomía Patológica, Hospital
Monte Naranco, 33013
Oviedo, Spain
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Wei Lu
- Shanghai Center for Disease Control and Prevention,
Shanghai
200336, China
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Cancer Institute,
Shanghai
200032, China
| | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Angela Cox
- CRUK/YCR Sheffield Cancer Research Centre, Department of
Oncology, University of Sheffield, Sheffield
S10 2RX, UK
| | - Simon S. Cross
- Academic Unit of Pathology, Department of Neuroscience,
University of Sheffield, Sheffield
S10 2HQ, UK
| | - Malcolm W. R. Reed
- CRUK/YCR Sheffield Cancer Research Centre, Department of
Oncology, University of Sheffield, Sheffield
S10 2RX, UK
| | - Irene L. Andrulis
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada
M5G 1X5
- Department of Molecular Genetics, University of Toronto,
Toronto, Ontario, Canada
M5S 1A8
| | - Julia A. Knight
- Division of Epidemiology, Dalla Lana School of Public Health,
University of Toronto, Toronto, Ontario,
Canada
M5T 3M7
- Prosserman Centre for Health Research, Lunenfeld-Tanenbaum
Research Institute of Mount Sinai Hospital, Toronto,
Ontario, Canada
M5G 1X5
| | - Gord Glendon
- Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research
Institute of Mount Sinai Hospital, Toronto, Ontario,
Canada
M5G 1X5
| | - Sandrine Tchatchou
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada
M5G 1X5
| | - Elinor J. Sawyer
- Division of Cancer Studies, NIHR Comprehensive Biomedical
Research Centre, Guy’s & St Thomas’ NHS Foundation
Trust in partnership with King's College London, London
SE1 9RT, UK
| | - Ian Tomlinson
- Wellcome Trust Centre for Human Genetics, Oxford Biomedical
Research Centre, University of Oxford, Oxford
OX3 7BN, UK
| | - Michael J. Kerin
- Clinical Science Institute, University Hospital Galway,
Galway, Ireland
| | - Nicola Miller
- Clinical Science Institute, University Hospital Galway,
Galway, Ireland
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Fredrick Schumacher
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Loic Le Marchand
- Epidemiology Program, Cancer Research Center, University of
Hawaii, Honolulu, Hawaii
96813, USA
| | - Annika Lindblom
- Department of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Sara Margolin
- Department of Oncology—Pathology, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Soo Hwang TEO
- Breast Cancer Research Unit, University Malaya Cancer Research
Institute, University Malaya Medical Centre, 59100
Kuala Lumpur, Malaysia
- Cancer Research Initiatives Foundation, Sime Darby Medical
Centre, Subang Jaya
47500
Selangor, Malaysia
| | - Cheng Har YIP
- Breast Cancer Research Unit, University Malaya Cancer Research
Institute, University Malaya Medical Centre, 59100
Kuala Lumpur, Malaysia
| | - Daphne S. C. Lee
- Cancer Research Initiatives Foundation, Sime Darby Medical
Centre, Subang Jaya
47500
Selangor, Malaysia
| | - Tien Y. Wong
- Singapore Eye Research Institute, National University of
Singapore, Singapore
168751, Singapore
| | - Maartje J. Hooning
- Department of Medical Oncology, Erasmus MC Cancer
Institute, 3008 AE
Rotterdam, The Netherlands
| | - John W. M. Martens
- Department of Medical Oncology, Erasmus MC Cancer
Institute, 3008 AE
Rotterdam, The Netherlands
| | - J. Margriet Collée
- Department of Clinical Genetics, Erasmus University Medical
Center, 3000 CA
Rotterdam, The Netherlands
| | | | - John L. Hopper
- Centre for Molecular, Environmental, Genetic and Analytical
Epidemiology, Melbourne School of Population Health, University of
Melbourne, Melbourne, Victoria
3010, Australia
| | - Melissa C. Southey
- Department of Pathology, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Helen Tsimiklis
- Department of Pathology, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Miroslav K. Kapuscinski
- Centre for Molecular, Environmental, Genetic and Analytical
Epidemiology, Melbourne School of Population Health, University of
Melbourne, Melbourne, Victoria
3010, Australia
| | - Chen-Yang Shen
- College of Public Health, China Medical University,
Taichung
40402, Taiwan, China
- Institute of Biomedical Sciences, Academia Sinica,
Taipei
115, Taiwan, China
| | - Pei-Ei Wu
- Taiwan Biobank, Institute of Biomedical Sciences, Academia
Sinica, Taipei
115, Taiwan, China
| | - Jyh-Cherng Yu
- Department of Surgery, Tri-Service General Hospital,
Taipei
114, Taiwan, China
| | - Shou-Tung Chen
- Department of Surgery, Changhua Christian Hospital,
Changhua City
500, Taiwan, China
| | - Grethe Grenaker Alnæs
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
| | - Anne-Lise Borresen-Dale
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
- Institute of Clinical Medicine, University of Oslo (UiO),
0318
Oslo, Norway
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria,
Melbourne, Victoria
3004, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Roger L. Milne
- Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne,
Melbourne, Victoria
3010, Australia
- Cancer Epidemiology Centre, The Cancer Council Victoria,
Melbourne, Victoria
3053, Australia
| | - Catriona McLean
- Anatomical Pathology, The Alfred Hospital,
Melbourne, Victoria
3004, Australia
| | - Kenneth Muir
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
- Institute of Population Health, University of Manchester,
Manchester
M13 9PL, UK
| | - Artitaya Lophatananon
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
| | - Sarah Stewart-Brown
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
| | | | - Mikael Hartman
- Department of Surgery, Yong Loo Lin School of Medicine,
National University of Singapore and National University Health System,
Singapore
119228, Singapore
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
| | - Hui Miao
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
| | | | - Yik Ying Teo
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
- Department of Statistics and Applied Probability, National
University of Singapore, Singapore
117546, Singapore
| | - Peter A. Fasching
- Division of Hematology and Oncology, Department of Medicine,
David Geffen School of Medicine, University of California at Los Angeles,
Los Angeles, California
90095, USA
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Lothar Haeberle
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Arif B. Ekici
- Institute of Human Genetics, University Hospital Erlangen,
Friedrich Alexander University Erlangen-Nuremberg, 91054
Erlangen, Germany
| | - Matthias W. Beckmann
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
- German Cancer Consortium (DKTK), 69120
Heidelberg, Germany
| | - Aida Karina Dieffenbach
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
- German Cancer Consortium (DKTK), 69120
Heidelberg, Germany
| | - Volker Arndt
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
| | | | - Anthony Swerdlow
- Division of Breast Cancer Research, Institute of Cancer
Research, London
SM2 5NG, UK
- Division of Genetics and Epidemiology, Institute of Cancer
Research, London
SM2 5NG, UK
| | - Alan Ashworth
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
| | - Nick Orr
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
| | - Minouk J. Schoemaker
- Division of Genetics and Epidemiology, Institute of Cancer
Research, London
SM2 5NG, UK
| | - Montserrat García-Closas
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
- Division of Genetics and Epidemiology, Institute of Cancer
Research, Sutton, Surrey
SM2 5NG, UK
| | - Jonine Figueroa
- Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, Maryland
20850, USA
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, Maryland
20850, USA
| | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M.
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
02-781
Warsaw, Poland
| | - Jacques Simard
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire
de Québec Research Center, Laval University, Quebec,
Canada
G1V 4G2
| | - Mark S. Goldberg
- Department of Medicine, McGill University,
Montreal, Quebec, Canada
H3G 2M1
- Division of Clinical Epidemiology, McGill University Health
Centre, Royal Victoria Hospital, Montreal, Quebec,
Canada
H3A 1A8
| | - France Labrèche
- Département de médecine sociale et
préventive, Département de santé environnementale et
santé au travail, Université de Montréal,
Montreal, Quebec, Canada
H3T 1A8
| | - Martine Dumont
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire
de Québec Research Center, Laval University, Quebec,
Canada
G1V 4G2
| | - Robert Winqvist
- Laboratory of Cancer Genetics and Tumor Biology, Department of
Clinical Chemistry and Biocenter Oulu, NordLab Oulu/Oulu University Hospital,
University of Oulu, FI-90220
Oulu, Finland
| | - Katri Pylkäs
- Laboratory of Cancer Genetics and Tumor Biology, Department of
Clinical Chemistry and Biocenter Oulu, NordLab Oulu/Oulu University Hospital,
University of Oulu, FI-90220
Oulu, Finland
| | - Arja Jukkola-Vuorinen
- Department of Oncology, Oulu University Hospital, University
of Oulu, FI-90220
Oulu, Finland
| | - Hiltrud Brauch
- Dr Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, 70376
Stuttgart, Germany
- University of Tübingen, 72074
Tübingen, Germany
- German Cancer Consortium (DKTK) and German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
| | - Thomas Brüning
- Institute for Prevention and Occupational Medicine of the
German Social Accident Insurance, Institute of the Ruhr University Bochum
(IPA), 44789
Bochum, Germany
| | - Yon-Dschun Koto
- Department of Internal Medicine, Evangelische Kliniken Bonn
gGmbH, Johanniter Krankenhaus, 53113
Bonn, Germany
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing,
Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto
Nazionale dei Tumori (INT), 20133
Milan, Italy
| | - Paolo Peterlongo
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare,
20139
Milan, Italy
| | - Bernardo Bonanni
- Division of Cancer Prevention and Genetics, Istituto Europeo
di Oncologia (IEO), 20141
Milan, Italy
| | - Sara Volorio
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare,
20139
Milan, Italy
- Cogentech Cancer Genetic Test Laboratory,
20133
Milan, Italy
| | - Thilo Dörk
- Department of Obstetrics and Gynaecology, Hannover Medical
School, 30625
Hannover, Germany
| | - Natalia V. Bogdanova
- Department of Radiation Oncology, Hannover Medical
School, 30625
Hannover, Germany
| | - Sonja Helbig
- Department of Obstetrics and Gynaecology, Hannover Medical
School, 30625
Hannover, Germany
| | - Arto Mannermaa
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Vesa Kataja
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Veli-Matti Kosma
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Jaana M. Hartikainen
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Peter Devilee
- Department of Human Genetics & Department of
Pathology, Leiden University Medical Center, 2300 RC
Leiden, The Netherlands
| | | | - Caroline Seynaeve
- Family Cancer Clinic, Department of Medical Oncology, Erasmus
MC-Daniel den Hoed Cancer Centre, 3075 EA
Rotterdam, The Netherlands
| | - Christi J. Van Asperen
- Department of Clinical Genetics, Erasmus University Medical
Center, 3000 CA
Rotterdam, The Netherlands
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | | | - Katarzyna Durda
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | - Susan Slager
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Amanda E. Toland
- Department of Molecular Virology, Immunology and Medical
Genetics, Comprehensive Cancer Center, The Ohio State University,
Columbus, Ohio
43210, USA
| | | | - Drakoulis Yannoukakos
- Molecular Diagnostics Laboratory, IRRP, National Centre for
Scientific Research ‘Demokritos’, Aghia Paraskevi
Attikis, Athens
15310, Greece
| | | | | | - Paul Brennan
- International Agency for Research on Cancer,
Lyon, Cedex 08, France
| | - James McKay
- International Agency for Research on Cancer,
Lyon, Cedex 08, France
| | - Ute Hamann
- Molecular Genetics of Breast Cancer, German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
| | - Diana Torres
- Molecular Genetics of Breast Cancer, German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
- Institute of Human Genetics, Pontificia University
Javeriana, Bogota, DC
11001000, Colombia
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Jirong Long
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Hoda Anton-Culver
- Department of Epidemiology, University of California
Irvine, Irvine, California
92697, USA
| | - Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute
of City of Hope, Duarte, California
92697, USA
| | - Craig Luccarini
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Caroline Baynes
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Shahana Ahmed
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Mel Maranian
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Catherine S. Healey
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Anna González-Neira
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Guillermo Pita
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - M. Rosario Alonso
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Nuria Álvarez
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Daniel Herrero
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Daniel C. Tessier
- Centre d’innovation Génome Québec
et Université McGill, Montréal,
Quebec, Canada
H3A OG1
| | | | | | - Ines de Santiago
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Jason Carroll
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Carlos Caldas
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Melissa A. Brown
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Mathieu Lupien
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
- Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research
Institute of Mount Sinai Hospital, Toronto, Ontario,
Canada
M5G 1X5
- Department of Medical Biophysics, University of Toronto,
Toronto, Ontario, Canada
M5G 1L7
| | - Vessela N. Kristensen
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
- Institute of Clinical Medicine, University of Oslo (UiO),
0318
Oslo, Norway
- Department of Clinical Molecular Biology (EpiGen), University
of Oslo (UiO), 0450
Oslo, Norway
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Georgia Chenevix-Trench
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Juliet D French
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Douglas F. Easton
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Alison M. Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| |
Collapse
|
19
|
Reeves ME, Firek M, Chen ST, Amaar YG. Evidence that RASSF1C stimulation of lung cancer cell proliferation depends on IGFBP-5 and PIWIL1 expression levels. PLoS One 2014; 9:e101679. [PMID: 25007054 PMCID: PMC4090148 DOI: 10.1371/journal.pone.0101679] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Accepted: 06/11/2014] [Indexed: 12/24/2022] Open
Abstract
RASSF1C is a major isoform of the RASSF1 gene, and is emerging as an oncogene. This is in contradistinction to the RASSF1A isoform, which is an established tumor suppressor. We have previously shown that RASSF1C promotes lung cancer cell proliferation and have identified RASSF1C target genes with growth promoting functions. Here, we further report that RASSF1C promotes lung cancer cell migration and enhances lung cancer cell tumor sphere formation. We also show that RASSF1C over-expression reduces the inhibitory effects of the anti-cancer agent, betulinic acid (BA), on lung cancer cell proliferation. In previous work, we demonstrated that RASSF1C up-regulates piwil1 gene expression, which is a stem cell self-renewal gene that is over-expressed in several human cancers, including lung cancer. Here, we report on the effects of BA on piwil1 gene expression. Cells treated with BA show decreased piwil1 expression. Also, interaction of IGFBP-5 with RASSF1C appears to prevent RASSF1C from up-regulating PIWIL1 protein levels. These findings suggest that IGFBP-5 may be a negative modulator of RASSF1C/ PIWIL1 growth-promoting activities. In addition, we found that inhibition of the ATM-AMPK pathway up-regulates RASSF1C gene expression.
Collapse
Affiliation(s)
- Mark E. Reeves
- Surgical Oncology Laboratory, Loma Linda VA Medical Center, Loma Linda, California, United States of America
- Department of Surgery, Loma Linda University School of Medicine, Loma Linda, California, United States of America
| | - Matthew Firek
- Surgical Oncology Laboratory, Loma Linda VA Medical Center, Loma Linda, California, United States of America
| | - Shin-Tai Chen
- Musculoskeletal Disease Center, Loma Linda VA Medical Center, Loma Linda, California, United States of America
| | - Yousef G. Amaar
- Surgical Oncology Laboratory, Loma Linda VA Medical Center, Loma Linda, California, United States of America
- Department of Surgery, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- * E-mail:
| |
Collapse
|
20
|
Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLoS One 2014; 9:e87754. [PMID: 24551065 PMCID: PMC3923757 DOI: 10.1371/journal.pone.0087754] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 01/02/2014] [Indexed: 01/12/2023] Open
Abstract
Systemic sclerosis (SSc) is characterized by excessive fibrosis of the skin and internal organs due to fibroblast proliferation and excessive production of extracellular matrix (ECM). We have shown that insulin-like growth factor binding protein (IGFBP)-5 plays an important role in the development of fibrosis in vitro, ex vivo, and in vivo. We identified a membrane-associated adaptor protein, downstream of tyrosine kinase/docking protein (DOK)5, as an IGFBP-5-regulated target gene using gene expression profiling of primary fibroblasts expressing IGFBP-5. DOK5 is a tyrosine kinase substrate associated with intracellular signaling. Our objective was to determine the role of DOK5 in the pathogenesis of SSc and specifically in IGFBP-5-induced fibrosis. DOK5 mRNA and protein levels were increased in vitro by endogenous and exogenous IGFBP-5 in primary human fibroblasts. DOK5 upregulation required activation of the mitogen-activated protein kinase (MAPK) signaling cascade. Further, IGFBP-5 triggered nuclear translocation of DOK5. DOK5 protein levels were also increased in vivo in mouse skin and lung by IGFBP-5. To determine the effect of DOK5 on fibrosis, DOK5 was expressed ex vivo in human skin in organ culture. Expression of DOK5 in human skin resulted in a significant increase in dermal thickness. Lastly, levels of DOK5 were compared in primary fibroblasts and lung tissues of patients with SSc and healthy donors. Both DOK5 mRNA and protein levels were significantly increased in fibroblasts and skin tissues of patients with SSc compared with those of healthy controls, as well as in lung tissues of SSc patients. Our findings suggest that IGFBP-5 induces its pro-fibrotic effects, at least in part, via DOK5. Furthermore, IGFBP-5 and DOK5 are both increased in SSc fibroblasts and tissues and may thus be acting in concert to promote fibrosis.
Collapse
Affiliation(s)
- Hidekata Yasuoka
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Yukie Yamaguchi
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
| | - Carol A. Feghali-Bostwick
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America
- * E-mail:
| |
Collapse
|
21
|
Abstract
This study examined whether IGF-binding protein 5 (IGFBP5) is involved in the high glucose-induced deteriorating effects in cardiac cells. Cardiac fibroblasts and cardiomyocytes were isolated from the hearts of 1- to 3-day-old Sprague Dawley rats. Treatment of fibroblasts with 25 mM glucose increased the number of cells and the mRNA levels of collagen III, matrix metalloproteinase 2 (MMP2), and MMP9. High glucose increased ERK1/2 activity, and the ERK1/2 inhibitor PD98059 suppressed high glucose-mediated fibroblast proliferation and increased collagen III mRNA levels. Whereas high glucose increased both mRNA and protein levels of IGFBP5 in fibroblasts, high glucose did not affect IGFBP5 protein levels in cardiomyocytes. The high glucose-induced increase in IGFBP5 protein levels was inhibited by PD98059 in fibroblasts. While recombinant IGFBP5 increased ERK phosphorylation, cell proliferation, and the mRNA levels of collagen III, MMP2, and MMP9 in fibroblasts, IGFBP5 increased c-Jun N-terminal kinase phosphorylation and induced apoptosis in cardiomyocytes. The knockdown of IGFBP5 inhibited high glucose-induced cell proliferation and collagen III mRNA levels in fibroblasts. Although high glucose increased IGF1 levels, IGF1 did not increase IGFBP5 levels in fibroblasts. The hearts of Otsuka Long-Evans Tokushima Fatty rats and the cardiac fibroblasts of streptozotocin-induced diabetic rats showed increased IGFBP5 expression. These results suggest that IGFBP5 mediates high glucose-induced profibrotic effects in cardiac fibroblasts.
Collapse
Affiliation(s)
- Seung Eun Song
- Department of Physiology, College of Medicine, Yeungnam University, Daegu 705-717, South Korea
| | | | | | | | | | | |
Collapse
|
22
|
Lee SR, Kim SH, Chae HD, Kim CH, Kang BM. Influence of vascular endothelial growth factor on the expression of insulin-like growth factor-II, insulin-like growth factor binding protein-2 and 5 in human luteinized granulosa cells. Gynecol Endocrinol 2012; 28:917-20. [PMID: 22571677 DOI: 10.3109/09513590.2012.683070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The aim of the present study was to investigate the influence of vascular endothelial growth factor (VEGF) on the expression of insulin-like growth factor (IGF)-II, insulin-like growth factor binding protein (IGFBP)-2 and in cultured human luteinized granulosa cells (LGCs). Human LGCs were obtained from the follicular fluid by transvaginal oocyte aspiration from 30 infertile patients undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). The cells were cultured for 72 h with VEGF at concentrations of 0.1, 1.0, and 10.0 ng/ml. The cells not treated with VEGF served as controls. Reverse transcription-polymerase chain reaction (RT-PCR) was used to examine the expression of IGF-II, IGFBP-2, and 5 mRNA. The expression of IGF-II mRNA in the 10.0 ng/ml of VEGF group was significantly higher than that in the control group. Treatment with 10.0 ng/ml of VEGF significantly increased the expression of IGFBP-5 mRNA than all other groups. There were no statistically significant differences in the expression of IGFBP-2 mRNA among all the groups. VEGF may play a regulator role in human ovarian physiology by modulating the expression of IGF-II and IGFBP-5 in LGCs.
Collapse
Affiliation(s)
- Sa-Ra Lee
- Department of Obstetrics and Gynecology, Ewha Womans University, School of Medicine, Ewha Womans University Mokdong Hospital 911-1 Mokdong, YangCheon-Ku, Seoul, Republic of Korea
| | | | | | | | | |
Collapse
|
23
|
Sokolović A, Montenegro-Miranda PS, de Waart DR, Cappai RMN, Duijst S, Sokolović M, Bosma PJ. Overexpression of insulin like growth factor binding protein 5 reduces liver fibrosis in chronic cholangiopathy. Biochim Biophys Acta 2012; 1822:996-1003. [PMID: 22434064 DOI: 10.1016/j.bbadis.2012.02.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2011] [Revised: 02/12/2012] [Accepted: 02/26/2012] [Indexed: 01/01/2023]
Abstract
The ATP-binding cassette, sub-family B member 4 knock-out mouse (Abcb4(-/-)) is a relevant model for chronic cholangiopathy in man. Due to the lack of this P-glycoprotein in the canalicular membrane of hepatocytes, the secretion of phospholipids into bile is absent, resulting in increased bile toxicity. Expression of insulin like growth factor binding protein 5 (Igfbp5) increases in time in the livers of these mice. It is unclear whether this induction is a consequence of or plays a role in the progression of liver pathology. The aim of this study was therefore to investigate the effect of IGFBP5 induction on the progression of liver fibrosis caused by chronic cholangiopathy. IGFBP5 and, as a control, green fluorescent protein were overexpressed in the hepatocytes of Abcb4(-/-) mice, using an adeno-associated viral vector (AAV). Progression of liver fibrosis was studied 3, 6, and 12 weeks after vector injection by analyzing serum parameters, collagen deposition, expression of pro-fibrotic genes, inflammation and oxidative stress. A single administration of the AAV vectors provided prolonged expression of IGFBP5 and GFP in the livers of Abcb4(-/-) mice. Compared to GFP control, fractional liver weight, extracellular matrix deposition and amount of activated hepatic stellate cells significantly decreased in IGFBP5 overexpressing mice even 12 weeks after treatment. This effect was not due to a change in bile composition, but driven by reduced inflammation, oxidative stress, and proliferation. Overexpression of IGFBP5 seems to have a protective effect on liver pathology in this model for chronic cholangiopathy.
Collapse
Affiliation(s)
- Aleksandar Sokolović
- Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
24
|
Brito I, Gil-Peña H, Molinos I, Loredo V, Henriques-Coelho T, Caldas-Afonso A, Santos F. Growth cartilage expression of growth hormone/insulin-like growth factor I axis in spontaneous and growth hormone induced catch-up growth. Growth Horm IGF Res 2012; 22:129-133. [PMID: 22583947 DOI: 10.1016/j.ghir.2012.04.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Revised: 12/21/2011] [Accepted: 04/19/2012] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Catch-up growth following the cessation of a growth inhibiting cause occurs in humans and animals. Although its underlying regulatory mechanisms are not well understood, current hypothesis confer an increasing importance to local factors intrinsic to the long bones' growth plate (GP). AIM The present study was designed to analyze the growth-hormone (GH)-insulin-like growth factor I (IGF-I) axis in the epiphyseal cartilage of young rats exhibiting catch-up growth as well as to evaluate the effect of GH treatment on this process. MATERIAL AND METHODS Female Sprague-Dawley rats were randomly grouped: controls (group C), 50% diet restriction for 3 days+refeeding (group CR); 50% diet restriction for 3 days+refeeding & GH treatment (group CRGH). Analysis of GH receptor (GHR), IGF-I, IGF-I receptor (IGF-IR) and IGF binding protein 5 (IGFBP5) expressions by real-time PCR was performed in tibial growth plates extracted at the time of catch-up growth, identified by osseous front advance greater than that of C animals. RESULTS In the absence of GH treatment, catch-up growth was associated with increased IGF-I and IGFBP5 mRNA levels, without changes in GHR or IGF-IR. GH treatment maintained the overexpression of IGF-I mRNA and induced an important increase in IGF-IR expression. CONCLUSIONS Catch-up growth that happens after diet restriction might be related with a dual stimulating local effect of IGF-I in growth plate resulting from overexpression and increased bioavailability of IGF-I. GH treatment further enhanced expression of IGF-IR which likely resulted in a potentiation of local IGF-I actions. These findings point out to an important role of growth cartilage GH/IGF-I axis regulation in a rat model of catch-up growth.
Collapse
Affiliation(s)
- Iva Brito
- Pediatric Rheumatology Unit, Pediatric Department, Hospital São João, Porto, Portugal.
| | | | | | | | | | | | | |
Collapse
|
25
|
Sureshbabu A, Okajima H, Yamanaka D, Tonner E, Shastri S, Maycock J, Szymanowska M, Shand J, Takahashi SI, Beattie J, Allan G, Flint D. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci 2012; 125:1693-705. [PMID: 22328518 DOI: 10.1242/jcs.092882] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2024] Open
Abstract
Maintenance of tissue boundaries is crucial for control of metastasis. We describe a new signalling pathway in which epithelial cell disruption can be minimised and thereby restricts epithelial-mesenchymal transgressions. This involves the release of insulin-like growth factor (IGF)-binding protein 5 (IGFBP5) from apoptotic cells, which increases the adhesion of epithelial cells on mesenchymal but not epithelial extracellular matrix (ECM), and involves the direct interaction of IGFBP5 and α2β1 integrins. IGFBP5 also induced cell adhesion to vitronectin in the absence of αVβ3 integrin, the vitronectin receptor, again through an α2β1-integrin-dependent action, suggesting that IGFBP5 can induce spreading on matrices, even in the absence of the integrins normally used in this process. Using IGFBP5 mutants we demonstrate that the effect is IGF-independent but requires the heparin-binding domain in the C-terminus of IGFBP5. A truncated mutant containing only the C-terminal of IGFBP5 also induced adhesion. Adhesion induced by IGFBP5 was dependent on Cdc42 and resulted in activation of integrin-linked kinase (ILK) and Akt. Consistent with these changes, IGFBP5 facilitated prolonged cell survival in nutrient-poor conditions and decreased phosphorylation of the stress-activated kinase p38 MAPK (MAPK14). Whereas IGFBP5 enhanced adhesion, it inhibited cell migration, although this was not evident using the truncated C-terminal mutant, suggesting that effects of IGFBP5 on adhesion and migration involve different mechanisms. We anticipate that these responses to IGFBP5 would reduce the metastatic potential of cells.
Collapse
Affiliation(s)
- Angara Sureshbabu
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
López-Menduiña M, Martín AI, Castillero E, Villanúa MA, López-Calderón A. Short-term growth hormone or IGF-I administration improves the IGF-IGFBP system in arthritic rats. Growth Horm IGF Res 2012; 22:22-29. [PMID: 22244673 DOI: 10.1016/j.ghir.2011.12.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Revised: 12/08/2011] [Accepted: 12/14/2011] [Indexed: 01/15/2023]
Abstract
OBJECTIVE Adjuvant-induced arthritis is an experimental model of rheumatoid arthritis that inhibits the GH-IGF-I axis and decreases body weight gain and muscle mass. Although chronic GH or IGF-I treatment increases body weight gain in arthritic rats, muscle resistance to GH and IGF-I is a very common complication in inflammatory diseases. In this study we examine the effect of short-term administration of rhGH and rhIGF-I on liver and muscle IGF-I, IGFBP-3 and -5 as well as on the ubiquitin-ligases MuRF1 and atrogin-1 in the muscle of arthritic rats. DESIGN Arthritis was induced in adult male Wistar rats by an intradermal injection of 4 mg of Freund's adjuvant. Fifteen days after adjuvant injection, 300 μg/kg of rhGH or 200 μg/kg of rhIGF or saline was administrated 18 and 3h before decapitation. A pair-fed group injected with saline was included in order to discard a possible effect of decreased food intake. Gene expression of IGF-I, GHR, IGFBP-3, IGFBP-5, atrogin-1 and MuRF1 were quantified using RT-PCR. In serum, IGF-I was measured by radioimmunoassay (RIA) and IGFBP-3 by ligand blot. RESULTS Arthritis decreased serum IGF-I and IGF mRNA in liver (P<0.05), but not in skeletal muscle. In arthritic rats, rhGH increased serum IGF-I and liver IGF-I mRNA similar to the levels of pair-fed rats. Arthritis increased atrogin-1, MuRF1, IGFBP-3 and IGFBP-5 mRNA in muscle (P<0.01). IGFBP-3 mRNA was downregulated by rhIGF-I, but not by rhGH, administration in control and arthritic rats (P<0.05). Administration of rhGH and rhIGF-I increased IGFBP-5 in the gastrocnemius of arthritic rats. CONCLUSIONS Short-term rhGH and rhIGF-I administration was found to increase muscle IGFBP-5 mRNA, whereas only rhIGF-I administration decreased muscle IGFBP-3 mRNA in control and arthritic rats. These data suggest that arthritis does not induce GH or IGF-I resistance in skeletal muscle.
Collapse
Affiliation(s)
- M López-Menduiña
- Department of Physiology, Faculty of Medicine, Complutense University, Avda. Complutense s/n. 28040 Madrid, Spain
| | | | | | | | | |
Collapse
|
27
|
Bokov AF, Garg N, Ikeno Y, Thakur S, Musi N, DeFronzo RA, Zhang N, Erickson RC, Gelfond J, Hubbard GB, Adamo ML, Richardson A. Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One 2011; 6:e26891. [PMID: 22132081 PMCID: PMC3223158 DOI: 10.1371/journal.pone.0026891] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2011] [Accepted: 10/05/2011] [Indexed: 12/21/2022] Open
Abstract
Mutations in insulin/IGF-1 signaling pathway have been shown to lead to increased longevity in various invertebrate models. Therefore, the effect of the haplo- insufficiency of the IGF-1 receptor (Igf1r+/−) on longevity/aging was evaluated in C57Bl/6 mice using rigorous criteria where lifespan and end-of-life pathology were measured under optimal husbandry conditions using large sample sizes. Igf1r+/− mice exhibited reductions in IGF-1 receptor levels and the activation of Akt by IGF-1, with no compensatory increases in serum IGF-1 or tissue IGF-1 mRNA levels, indicating that the Igf1r+/− mice show reduced IGF-1 signaling. Aged male, but not female Igf1r+/− mice were glucose intolerant, and both genders developed insulin resistance as they aged. Female, but not male Igf1r+/− mice survived longer than wild type mice after lethal paraquat and diquat exposure, and female Igf1r+/− mice also exhibited less diquat-induced liver damage. However, no significant difference between the lifespans of the male Igf1r+/− and wild type mice was observed; and the mean lifespan of the Igf1r+/− females was increased only slightly (less than 5%) compared to wild type mice. A comprehensive pathological analysis showed no significant difference in end-of-life pathological lesions between the Igf1r+/− and wild type mice. These data show that the Igf1r+/− mouse is not a model of increased longevity and delayed aging as predicted by invertebrate models with mutations in the insulin/IGF-1 signaling pathway.
Collapse
Affiliation(s)
- Alex F. Bokov
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Neha Garg
- Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Yuji Ikeno
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Geriatric Research, Education, and Clinical Center (GRECC), South Texas Veterans Health Care System, San Antonio, Texas, United States of America
| | - Sachin Thakur
- Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Nicolas Musi
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Geriatric Research, Education, and Clinical Center (GRECC), South Texas Veterans Health Care System, San Antonio, Texas, United States of America
| | - Ralph A. DeFronzo
- Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Ning Zhang
- Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Rebecca C. Erickson
- College of Natural Sciences, University of Texas at Austin, Austin, Texas, United States of America
| | - Jon Gelfond
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Gene B. Hubbard
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Martin L. Adamo
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Arlan Richardson
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
- Geriatric Research, Education, and Clinical Center (GRECC), South Texas Veterans Health Care System, San Antonio, Texas, United States of America
- * E-mail:
| |
Collapse
|
28
|
Rahman MS, Thomas P. Characterization of three IGFBP mRNAs in Atlantic croaker and their regulation during hypoxic stress: potential mechanisms of their upregulation by hypoxia. Am J Physiol Endocrinol Metab 2011; 301:E637-48. [PMID: 21730259 DOI: 10.1152/ajpendo.00168.2011] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Insulin-like growth factor-binding proteins (IGFBPs) play important roles in downregulating IGF activity and growth and development in vertebrates under hypoxic stress. However, the mechanisms of hypoxia regulation of IGFBPs in teleost fishes are unknown. The involvement of reactive oxygen species (ROS) and hypoxia-inducible factors (HIFs) in hypoxia upregulation of IGFBPs in Atlantic croaker were investigated. Three croaker IGFBPs, IGFBP-1, IGFBP-2, and IGFBP-5, were cloned and characterized. Chronic hypoxia exposure [dissolved oxygen (DO): 1.7 mg/l for 2-4 wk] caused significant increases in hepatic and neural IGFBP-1 mRNA expression compared with tissue mRNA levels in fish held under normoxic conditions (6.5 mg DO/l). Moreover, longer-term chronic hypoxia exposure (2-2.7 mg DO/l for 15-20 wk) caused significant increases in mRNA levels of all three IGFBPs in both liver and brain tissues. Hypoxia exposure also markedly increased superoxide radical (O(2)(·-), an index of ROS) production and HIF-1α mRNA and HIF-2α protein expression in croaker livers. Pharmacological treatment with an antioxidant attenuated the hypoxia-induced increases in O(2)(·-) production and HIFα mRNA and protein expression as well as the elevation of IGFBP-1 mRNA levels. These results suggest that the upregulation of IGFBP expression under hypoxia stress is due, in part, to alterations in the antioxidant status, which may involve ROS and HIFs.
Collapse
Affiliation(s)
- Md Saydur Rahman
- University of Texas at Austin, Marine Science Institute, Port Aransas, 78373, USA.
| | | |
Collapse
|
29
|
Conover CA, Boldt HB, Bale LK, Clifton KB, Grell JA, Mader JR, Mason EJ, Powell DR. Pregnancy-associated plasma protein-A2 (PAPP-A2): tissue expression and biological consequences of gene knockout in mice. Endocrinology 2011; 152:2837-44. [PMID: 21586553 DOI: 10.1210/en.2011-0036] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Pregnancy-associated plasma protein-A2 (PAPP-A2) is a novel homolog of PAPP-A in the metzincin superfamily. However, compared with the accumulating data on PAPP-A, very little is known about PAPP-A2. In this study, we determined the tissue expression pattern of PAPP-A2 mRNA in wild-type (WT) mice and characterized the phenotype of mice with global PAPP-A2 deficiency. Tissues expressing PAPP-A2 in WT mice were more limited than those expressing PAPP-A. The highest PAPP-A2 mRNA expression was found in the placenta, with abundant expression in fetal, skeletal, and reproductive tissues. Heterozygous breeding produced the expected Mendelian distribution for the pappa2 gene and viable homozygous PAPP-A2 knockout (KO) mice that were normal size at birth. The most striking phenotype of the PAPP-A2 KO mouse was postnatal growth retardation. Male and female PAPP-A2 KO mice had 10 and 25-30% lower body weight, respectively, than WT littermates. Adult femur and body length were also reduced in PAPP-A2 KO mice, but without significant effects on bone mineral density. PAPP-A2 KO mice were fertile, but with compromised fecundity. PAPP-A expression was not altered to compensate for the loss of PAPP-A2 expression, and proteolysis of PAPP-A2's primary substrate, IGF-binding protein-5, was not altered in fibroblasts from PAPP-A2 KO embryos. In conclusion, tissue expression patterns and biological consequences of gene KO indicate distinct physiological roles for PAPP-A2 and PAPP-A in mice.
Collapse
Affiliation(s)
- Cheryl A Conover
- Endocrine Research Unit, Division of Endocrinology, Metabolism, and Nutrition, College of Medicine Mayo Clinic, 200 First Street SW, 5-194 Joseph, Rochester, Minnesota 55905, USA.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 2010; 17:361-71. [PMID: 20228124 DOI: 10.1677/erc-10-0018] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Non-functioning pituitary adenomas (NFPAs) may be locally invasive. Markers of invasiveness are needed to guide patient management and particularly the use of adjuvant radiotherapy. To examine whether invasive NFPAs display a specific gene expression profile relative to non-invasive tumors, we selected 40 NFPAs (38 of the gonadotroph type) and classified them as invasive (n=22) or non-invasive (n=18) on the basis of magnetic resonance imaging and surgical findings. We then performed pangenomic analysis with the 44k Agilent human whole genome expression oligonucleotide microarray in order to identify genes with differential expression between invasive and non-invasive NFPAs. Candidate genes were then tested in qRT-PCR. Prediction class analysis showed that the expression of 346 genes differed between invasive and non-invasive NFPAs (P<0.001), of which 233 genes were up-regulated and 113 genes were down-regulated in invasive tumors. On the basis of Ingenuity networks and the degree of up- or down-regulation in invasive versus non-invasive tumors, 35 genes were selected for expression quantification by qRT-PCR. Overexpression of only four genes was confirmed, namely IGFBP5 (P=0.02), MYO5A (P=0.04), FLT3 (P=0.01), and NFE2L1 (P=0.02). At the protein level, only myosin 5A (MYO5A) immunostaining was stronger in invasive than in non-invasive NFPAs. Molecular signature allows to differentiate 'grossly' invasive from non-invasive NFPAs. The product of one of these genes, MYO5A, may be a useful marker of tumor invasiveness.
Collapse
|
31
|
Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, Tibollo P, Battistelli M, Falcieri E, Battistin L, Agnati LF, Stocchi V. C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. Exp Cell Res 2010; 316:1977-84. [PMID: 20399774 DOI: 10.1016/j.yexcr.2010.04.006] [Citation(s) in RCA: 204] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2009] [Revised: 04/03/2010] [Accepted: 04/10/2010] [Indexed: 12/28/2022]
Abstract
Micro-vesicles can be released by different cell types and operate as 'safe containers' mediating inter-cellular communication. In this work we investigated whether cultured myoblasts could release exosomes. The reported data demonstrate, for the first time, that C2C12 myoblasts release micro-vesicles as shown by the presence of two exosome markers (Tsg101 and Alix proteins). Using real-time PCR analysis it was shown that these micro-vesicles, like other cell types, carry mtDNA. Proteomic characterization of the released micro-vesicle contents showed the presence of many proteins involved in signal transduction. The bioinformatics assessment of the Disorder Index and Aggregation Index of these proteins suggested that C2C12 micro-vesicles mainly deliver the machinery for signal transduction to target cells rather than key proteins involved in hub functions in molecular networks. The presence of IGFBP-5 in the purified micro-vesicles represents an exception, since this binding protein can play a key role in the modulation of the IGF-1 signalling pathway. In conclusion, the present findings demonstrate that skeletal muscle cells release micro-vesicles, which probably have an important role in the communication processes within skeletal muscles and between skeletal muscles and other organs. In particular, the present findings suggest possible new diagnostic approaches to skeletal muscle diseases.
Collapse
Affiliation(s)
- M Guescini
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Mori G, Centonze M, Brunetti G, Ballini A, Oranger A, Mori C, Lo Muzio L, Tetè S, Ciccolella F, Colucci S, Grano M, Grassi FR. Osteogenic properties of human dental pulp stem cells. J BIOL REG HOMEOS AG 2010; 24:167-175. [PMID: 20487630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Stem cells are a promising tool for bone tissue regeneration. Dental pulp stem cells (DPSCs) can be easily obtained even in human young adults. In this study we investigated the capability of DPSCs, to express the osteoblastic phenotype when cultured with osteogenic medium. DPSCs isolated from the dental pulp of impacted third molar teeth were cultured with appropriate medium to induce osteoblast differentiation. Using Western-Blot, RT-PCR and microarray analysis, we studied the expression of osteoblastic parameter, and by Von Kossa staining we evaluated the production of mineralized matrix nodules. The results were compared with controls represented by undifferentiated DPSCs. DPSCs, differentiated into osteoblast-like cells, express large amount of alkaline phosphatase (ALP), collagen I (Coll I), osteopontin (OPN) and osteocalcin (OCN), all these parameters characterizing the osteoblastic phenotype. Differentiated DPSCs express Runx2 and JunB, a member of the AP-1 complex; both the transcription factors are associated with osteoblast differentiation and skeletal morphogenesis. Moreover, DPSCs express insulin growth factor-binding protein 5 (IGFBP-5), one of the regulating proteins of IGFs function. Finally, DPSCs can form mineralized matrix nodules that are a feature exclusive to osteoblasts. DPSCs could represent a potential source of osteoblasts to be used for bone regeneration.
Collapse
Affiliation(s)
- Giorgio Mori
- Department of Biomedical Science, University of Foggia Medical School, Foggia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ahn BY, Elwi AN, Lee B, Trinh DLN, Klimowicz AC, Yau A, Chan JA, Magliocco A, Kim SW. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 2010; 70:3013-9. [PMID: 20354179 DOI: 10.1158/0008-5472.can-09-3108] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tamoxifen resistance is one of the overarching challenges in the treatment of patients with estrogen receptor (ER)-positive breast cancer. Through a genome-wide RNA interference screen to discover genes responsible for tamoxifen resistance in vitro, we identified insulin-like growth factor binding protein 5 (IGFBP5) as a determinant of drug sensitivity. Specific knockdown of IGFBP5 by retroviral infection with short hairpin RNA-expressing cassette in MCF7 human breast cancer cells (pRS-shIGFBP5) conferred tamoxifen resistance in vitro due to concomitant loss of ERalpha expression and signaling. IGFBP5 expression was also reduced in MCF7 cells selected for tamoxifen resistance in culture (TAMR). Both tamoxifen-resistant MCF7-TAMR and MCF7-pRS-shIGFBP5 cells could be resensitized to drug by treatment with exogenous recombinant IGFBP5 (rIGFBP5) protein. Treatment with rIGFBP5 protein in mouse tumor xenografts reversed the in vivo tamoxifen resistance of MCF7-pRS-shIGFBP5 cell-derived tumors by reducing tumor cell proliferation. IGFBP5 immunohistochemical staining in a cohort of 153 breast cancer patients showed that low IGFBP5 expression was associated with shorter overall survival after tamoxifen therapy. Thus, IGFBP5 warrants investigation as an agent to reverse tamoxifen resistance.
Collapse
Affiliation(s)
- Bo Young Ahn
- Department of Biochemistry and Molecular Biology, Laboratory Medicine, Clark H Smith Brain Tumour Centre, and Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Yan X, Baxter RC, Firth SM. Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab 2010; 95:1412-20. [PMID: 20103653 DOI: 10.1210/jc.2009-2277] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
CONTEXT During pregnancy, circulating IGF binding protein-5 (IGFBP-5) undergoes substantial molecular redistribution from ternary complexes to either binary complexes or the uncomplexed protein. OBJECTIVE This study aimed to characterize the proteolysis of circulating IGFBP-5 during pregnancy and to determine whether it can increase IGF bioavailability. DESIGN Biochemical methods were used to purify and characterize IGFBP-5 fragments and IGFBP-5-specific proteolytic activity from pregnancy plasma. RESULTS Circulating IGFBP-5 was fully proteolyzed at all stages of pregnancy. Cleavage after either Ser143 or Lys144 resulted in two complementary fragments. Of two pools of proteolytic activity (>150 kDa and approximately 40 kDa) identified in pregnancy plasma, only the greater than 150-kDa proteolytic activity was specific to pregnancy. The approximately 40-kDa proteolytic activity, also present in nonpregnancy plasma, appeared largely inactive against IGF-I-complexed IGFBP-5. The greater than 150-kDa proteolytic activity was inhibited by alpha-PAPP-A2 but not alpha-PAPP-A1 antibody, cleaved recombinant IGFBP-5 at Ser143-Lys144 similar to PAPP-A2, and was inactive against IGFBP-5 (Ala128), a PAPP-A2-resistant analog. Compared to nonpregnancy plasma, incubation with pregnancy plasma resulted in release of more bioactive IGF-I from IGF-I-IGFBP-5 complexes as measured by stimulation of IGF-I receptor phosphorylation. CONCLUSIONS Circulating IGFBP-5 is proteolyzed by PAPP-A2 during pregnancy, resulting in increased IGF bioavailability, which may have important consequences for the development of the fetus and/or the well-being of the mother.
Collapse
Affiliation(s)
- Xiaolang Yan
- Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia.
| | | | | |
Collapse
|
35
|
Castillero E, Martín AI, López-Menduiña M, Granado M, Villanúa MA, López-Calderón A. IGF-I system, atrogenes and myogenic regulatory factors in arthritis induced muscle wasting. Mol Cell Endocrinol 2009; 309:8-16. [PMID: 19501629 DOI: 10.1016/j.mce.2009.05.017] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Revised: 05/08/2009] [Accepted: 05/26/2009] [Indexed: 10/20/2022]
Abstract
The aim of this work was to analyse the evolution of the ubiquitin-proteasome, the myogenic regulatory factors, and the IGF-I system during the development of experimental arthritis. Arthritis was induced by adjuvant injection and rats were killed 10, 15 and 22 days later. Gastrocnemius was progressively atrophied in arthritic rats. Arthritis induced a rapid increase in muscular IGFBP-3 and IGFBP-5 and, to a lesser extent, in IGF-I mRNA. An increased expression of the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 was observed in the gastrocnemius from day 10, reaching its maximum value on day 15. Concomitantly, the proliferation marker PCNA and the early myogenic regulatory factor MyoD were also maximally increased on day 15. Myogenin, a late-acting myogenic regulatory factor, was maximally increased on days 15 and 22. These results suggest that muscle wasting in arthritis is secondary to an increase in muscle proteolysis, rather to a decrease in muscle regeneration.
Collapse
Affiliation(s)
- Estíbaliz Castillero
- Department of Physiology, Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Sureshbabu A, Okajima H, Yamanaka D, Shastri S, Tonner E, Rae C, Szymanowska M, Shand JH, Takahashi SI, Beattie J, Allan GJ, Flint DJ. IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochem Soc Trans 2009; 37:882-5. [PMID: 19614612 DOI: 10.1042/bst0370882] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Fibrosis involves activation of fibroblasts, increased production of collagen and fibronectin and transdifferentiation into contractile myofibroblasts. The process resembles aspects of wound-healing but remains unresolved and can be life-threatening when manifest in the kidneys, lungs and liver, in particular. The causes are largely unknown, but recent suggestions that repetitive micro-injury results in the eventual failure of epithelial cell repair due to replicative senescence are gaining favour. This is consistent with the onset of fibrotic diseases in middle age. Because epithelial injury often involves blood loss, inflammatory responses associated with the fibrotic response have been considered as therapeutic targets. However, this has proved largely unsuccessful and focus is now switching to earlier events in the process. These include EMT (epithelial-mesenchymal transition) and fibroblast activation in the absence of inflammation. TGFbeta1 (transforming growth factor-beta1) induces both EMT and fibroblast activation and is considered to be a major pro-fibrotic factor. Recently, IGFBP-5 [IGF (insulin-like growth factor)-binding protein-5] has also been shown to induce similar effects on TGFbeta1, and is strongly implicated in the process of senescence. It also stimulates migration of peripheral blood mononuclear cells, implicating it in the inflammatory response. In this paper, we examine the evidence for a role of IGFBP-5 in fibrosis and highlight its structural relationship with other matrix proteins and growth factors also implicated in tissue remodelling.
Collapse
|
37
|
Stein T, Salomonis N, Nuyten DSA, van de Vijver MJ, Gusterson BA. A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J Mammary Gland Biol Neoplasia 2009; 14:99-116. [PMID: 19408105 DOI: 10.1007/s10911-009-9120-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Accepted: 04/06/2009] [Indexed: 12/15/2022] Open
Abstract
Mouse mammary gland involution resembles a wound healing response with suppressed inflammation. Wound healing and inflammation are also associated with tumour development, and a 'wound-healing' gene expression signature can predict metastasis formation and survival. Recent studies have shown that an involuting mammary gland stroma can promote metastasis. It could therefore be hypothesised that gene expression signatures from an involuting mouse mammary gland may provide new insights into the physiological pathways that promote breast cancer progression. Indeed, using the HOPACH clustering method, the human orthologues of genes that were differentially regulated at day 3 of mammary gland involution and showed prolonged expression throughout the first 4 days of involution distinguished breast cancers in the NKI 295 breast cancer dataset with low and high metastatic activity. Most strikingly, genes associated with copper ion homeostasis and with HIF-1 promoter binding sites were the most over-represented, linking this signature to hypoxia. Further, six out of the ten mRNAs with strongest up-regulation in cancers with poor survival code for secreted factors, identifying potential candidates that may be involved in stromal/matrix-enhanced metastasis formation/breast cancer development. This method therefore identified biological processes that occur during mammary gland involution, which may be critical in promoting breast cancer metastasis that could form a basis for future investigation, and supports a role for copper in breast cancer development.
Collapse
Affiliation(s)
- Torsten Stein
- Division of Cancer Sciences and Molecular Pathology, Section of Gene Regulation and Mechanisms of Disease, Western Infirmary, University of Glasgow, Glasgow, UK.
| | | | | | | | | |
Collapse
|
38
|
Pedroso FL, Fukada H, Masumoto T. Molecular characterization, tissue distribution patterns and nutritional regulation of IGFBP-1, -2, -3 and -5 in yellowtail, Seriola quinqueradiata. Gen Comp Endocrinol 2009; 161:344-53. [PMID: 19523384 DOI: 10.1016/j.ygcen.2009.01.010] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2008] [Revised: 01/20/2009] [Accepted: 01/21/2009] [Indexed: 12/28/2022]
Abstract
Insulin-like growth factor-binding proteins (IGFBPs) play a vital role in regulating the biological activities of IGFs. In this study, we cloned and determined full-length cDNA sequences of yellowtail IGFBP-1, -2, -3 and -5. Their tissue distribution was determined by real-time quantitative RT-PCR, which revealed that IGFBP-1, -2, -3 and -5 are widely distributed in yellowtail tissues. In yellowtail, both IGFBP-1 and -2 are highly expressed in the liver, IGFBP-3 is predominantly expressed in the heart and skin, with the lowest expression in the liver, and IGFBP-5 is highly expressed in the liver and kidneys. The widespread tissue expression of the yellowtail IGFBPs suggests that they may act in an autocrine and/or paracrine manner in the regulation of IGF activity. The effects of nutritional deprivation on yellowtail IGFBPs and IGF-I were also examined. During a 15-day starvation period, significant elevation was observed in hepatic yellowtail IGFBP-1. Refeeding restored its level to that of the control. No significant change was observed in the hepatic yellowtail IGFBP-2 mRNA levels in starved fish compared with control fish during the starvation period. Interestingly, during the early period of food deprivation, a significant increase was observed in hepatic yellowtail IGFBP-3 and -5 mRNA levels, concomitant to the significant elevation in hepatic IGF-I mRNA from day 3 to day 9. The unexpected increase in growth stimulatory IGFBPs and IGF-I during nutritional deprivation may represent a species-specific response to changes in nutritional condition.
Collapse
Affiliation(s)
- Fiona L Pedroso
- United Graduate School of Agricultural Sciences, Ehime University, 3-5-7 Tarumi, Matsuyama, Ehime, Japan
| | | | | |
Collapse
|
39
|
Hömme M, Schaefer F, Mehls O, Schmitt CP. Differential regulation of RGS-2 by constant and oscillating PTH concentrations. Calcif Tissue Int 2009; 84:305-12. [PMID: 19225708 DOI: 10.1007/s00223-009-9222-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2008] [Accepted: 01/18/2009] [Indexed: 02/07/2023]
Abstract
PTH has diverse effects on bone metabolism: anabolic when given intermittently, catabolic when given continuously. The cellular mechanisms underlying the varying target cell response are not clear yet. PTH induces RGS-2, a member of the Regulator of G-protein Signaling protein family, via cAMP/PKA, and inactivates PKC-mediated signaling. To investigate intracellular signaling pathways with different PTH concentration-time patterns, we treated UMR 106-01 osteoblast-like cells in a perfusion system. PTH was administered intermittently (4 min/h, 10(-7) M) or continuously at an equivalent cumulative dose (6.6 x 10(-9) M). cAMP was measured using radioimmunoassay, mRNA levels using real-time rtPCR and ribonuclease protection assay, and protein levels using Western immunoblotting. A single PTH pulse transiently increased cAMP levels by 2000% +/- 1200%. In contrast to continuous PTH exposure, cAMP induction remained unchanged with intermittent PTH, ruling out desensitization of the PTH receptor. In continuously perfused cells, RGS-2 abundance was three to five times higher than in cells intermittently exposed to PTH for up to 12 h. MKP-1 and -3 were significantly less induced with pulsatile PTH; exposure-mode-dependent differences in MMP-13 and IGFBP-5 were small. Pulsatile but not continuous PTH administration prevents PTHrP receptor desensitization and accumulation of RGS-2 in osteoblasts, which should preserve PKC-dependent signaling.
Collapse
Affiliation(s)
- M Hömme
- Division of Pediatric Nephrology, University Hospital for Pediatric and Adolescent Medicine, Im Neuenheimer Feld 153, 69120, Heidelberg, Germany.
| | | | | | | |
Collapse
|
40
|
Maeda H, Yonou H, Yano K, Ishii G, Saito S, Ochiai A. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5. Biochem Biophys Res Commun 2009; 381:311-6. [PMID: 19250630 DOI: 10.1016/j.bbrc.2009.01.096] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2009] [Accepted: 01/20/2009] [Indexed: 11/18/2022]
Abstract
In the bone matrix, insulin-like growth factors (IGFs) are the most abundant growth factors and IGF binding protein 5 (IGFBP-5) is the major IGFBP. Our previous study suggested that IGFs stored in the bone matrix and prostate-specific antigen (PSA) play an important role in prostate cancer (PC) bone metastasis. However, it is not clear how IGF signaling is activated in the bone microenvironment of PC metastasis. Therefore, we investigated whether PSA degrades IGFBP-5 and enhances biological activity of IGF. Enzymatically active PSA degraded the recombinant IGFBP-5 protein in a dose- and time-dependent manner and a serine protease inhibitor suppressed this degradation. Furthermore, PSA induced IGF-mediated type I IGF receptor phosphorylation that was inhibited by coincubation with IGFBP-5. The present study indicates PSA derived from PC cells can enhance IGF bioavailability in the bone microenvironment of PC metastasis, thereby permitting PC survival and malignant progression in the bone microenvironment.
Collapse
Affiliation(s)
- Hiroyuki Maeda
- Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
Fibrosis is associated with epithelial repair. It involves the activation of fibroblasts, increased production of extracellular matrix proteins and transdifferentiation to contractile, myofibroblasts that aid in wound contraction. This provisional matrix plugs the injured epithelium and provides a scaffold for epithelial cell migration, involving an epithelial-mesenchymal transition (EMT). When epithelial injury involves blood loss, this leads to platelet activation, the production of several growth factors and an acute inflammatory response. Under normal circumstances, the epithelial barrier is repaired and the inflammatory response resolves. However, in fibrotic disease, the fibroblast response continues, resulting in unresolved wound healing. The fibrotic diseases range from scleroderma, where the problem may be restricted to the skin and where it is not life-threatening, through to systemic forms that can manifest as, for example, idiopathic pulmonary fibrosis, in which death is inevitable within 3-5 years. Anti-inflammatory treatments have failed to ameliorate the disease condition and focus has instead turned to transforming growth factor-beta1 (TGFB1), since it induces many of the processes involved, including fibroblast activation and EMT. Most recently, however, a new player in this process has been described, IGF-binding protein-5 (IGFBP5). IGFBP5 has also been shown to induce similar effects to TGFB1, but, in addition, it is strongly implicated in the process of senescence which is now believed to be a significant factor in these diseases. We examine the evidence for this role of IGFBP5 and identify some of the therapeutic targets which might be used to ameliorate these diseases of unknown cause.
Collapse
|
42
|
Al-Shanti N, Saini A, Faulkner SH, Stewart CE. Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts--potential cross-talk with IGF system. Growth Factors 2008; 26:61-73. [PMID: 18428025 DOI: 10.1080/08977190802025024] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The interaction effects of tumour necrosis factor-alpha (TNF-alpha) and interlukin-6 (IL-6) on skeletal muscle proliferation and differentiation remains controversial. We therefore investigated the potential interactive effects of TNF-alpha and IL-6 on murine C2 skeletal myoblast survival, differentiation and proliferation. A novel and unexpected positive temporal interaction between TNF-alpha and IL-6 on cell growth was identified (90%), with maximal beneficial effects obtained in myoblasts treated with TNF-alpha (10 ng/ml) for 24 h prior to being dosed with IL-6 (2.5 ng/ml) for a further 24 h. This combined treatment significantly (p < 0.05) increased the level of total cellular protein (330%), extracellular signal-regulated kinase (ERK) phosphorylation (55%), and S-phase of cell cycle (2.5-fold), confirming cell growth. The expression of mRNAs of key regulators of muscle mass: insulin-like growth factor binding protein-5, insulin-like growth factor-II (IGF-II), IGF-I receptor (IGF-IR) and IGF-II receptor (IGF-IIR) were also significantly (p < 0.05) increased by 1600-, 1.6-, 27- and 6-fold, respectively, giving an indication of the regulatory mechanisms of this interaction. Moreover, in response to this treatment, the expression level of signal-transducing glycoprotein 130 (gp130) was induced up to 3.5-fold but not after either treatments alone. This may not only explain the beneficial effects of this treatment on skeletal myoblast numbers but also define a functional role of gp130 in skeletal muscle cells. Our data suggest that in the presence of TNF-alpha/IL-6 functions positively and potentially also cooperatively with the IGF system to achieve the maximal beneficial effect on skeletal myoblast numbers.
Collapse
Affiliation(s)
- Nasser Al-Shanti
- Institute for Biomedical Research into Human Movement and Health, Manchester Metropolitan University, Cheshire, England, UK.
| | | | | | | |
Collapse
|
43
|
Schlenska-Lange A, Knüpfer H, Lange TJ, Kiess W, Knüpfer M. Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro. Anticancer Res 2008; 28:1055-1060. [PMID: 18507054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND Malignant gliomas continue to be a therapeutic challenge. One of the major problems is the early and rapidly infiltrating tumor growth. The role of the insulinlike growth factor (IGF) system in the progression of malignant glioma growth is poorly understood. In this study we investigated the expression of different members of the IGF system in malignant glioma cells and the influence of IGF-I and -II on the proliferation and migration of human glioma cell lines in vitro. MATERIALS AND METHODS Expression of IGF-I and -II, IGF-receptor I and II and IGF binding proteins (IGFBP) 1 to 6 was analysed by PCR in cell lines T98G, A172, 86HG39 (glioblastoma multiforme) and U87MG (anaplastic astrocytoma). To investigate effects on cell-proliferation, the cells were treated with IGF-I or -II (0.001-100 ng/ml). The cell viability was assessed by MTT-assay. For testing migratory effects, the Boyden-chamber-assay with different combinations of IGF-I or -II or fetal calf serum (FCS) as chemotactic agents was used. RESULTS All cell lines expressed IGF-I- and IGF-II-receptor, whereas none of the cells expressed IGF-I or -II. IGFBP 2-6 were found in all cell lines. IGF-I treated cell lines T98G and 86HG39 showed a weak dose-independent enhanced proliferation compared to controls, whereas A172 did not respond. None of the investigated cell lines changed proliferation when treated with IGF-II. All IGF-I (100 ng/ml) treated cells showed increased migration compared to controls. This effect was markedly enhanced by supplementation with 0.5% FCS. Again, IGF-II had no effect. CONCLUSION These data demonstrate that IGF-I modulates proliferation and strongly stimulates migration of glioma cell lines in vitro.
Collapse
Affiliation(s)
- Anke Schlenska-Lange
- Hospital for Children and Adolescents, University of Leipzig, Liebigstr. 20 a, D-04103 Leipzig, Germany
| | | | | | | | | |
Collapse
|
44
|
Iosef C, Gkourasas T, Jia CYH, Li SSC, Han VKM. A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. Endocrinology 2008; 149:1214-26. [PMID: 18039785 DOI: 10.1210/en.2007-0959] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
IGF binding protein (IGFBP)-6 is a member of the IGFBP family that regulates the actions of IGFs. Although IGFBPs exert their functions extracellularly in an autocrine/paracrine manner, several members of the family, such as IGFBP-3 and -5, possess nuclear localization signals (NLS). To date, no NLS has been described for IGFBP-6, an IGFBP that binds preferentially to IGF-II. We report here that both exogenous and endogenous IGFBP-6 could be imported into the nuclei of rhabdomyosarcoma and HEK-293 cells. Nuclear import of IGFBP-6 was mediated by a NLS sequence that bears limited homology to those found in IGFBP-3 and -5. IGFBP-6 nuclear translocation was an active process that required importins. A peptide corresponding to the IGFBP-6 NLS bound preferentially to importin-alpha. A comprehensive peptide array study revealed that, in addition to positively charged residues such as Arg and Lys, amino acids, notably Gly and Pro, within the NLS, played an important part in binding to importins. Overexpression of wild-type IGFBP-6 increased apoptosis, and the addition of IGF-II did not negate this effect. Only the deletion of the NLS segment abolished the apoptosis effect. Taken together, these results suggest that IGFBP-6 is translocated to the nucleus with functional consequences and that different members of the IGFBP family have specific nuclear import mechanisms.
Collapse
Affiliation(s)
- Cristiana Iosef
- Department of Biochemistry, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada N6A 5C1
| | | | | | | | | |
Collapse
|
45
|
Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmölzer J, Haffner MC, Klocker H, Huber LA, Geley S, Doppler W. Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic 2007; 8:1815-1828. [PMID: 17892529 DOI: 10.1111/j.1600-0854.2007.00655.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In addition to its extracellular function as a secreted protein, IGF-binding protein (IGFBP)-5 has been postulated to act as a signaling molecule in the nucleus. This study aims to assess the significance of this postulated nuclear localization. By confocal immunofluorescence microscopy, we detected IGFBP-5 in the vesicular compartment of mammary epithelial cells in culture, while no nuclear staining was observed. Immunohistochemistry performed on paraffin sections of the involuting mammary gland revealed IGFBP-5 positive staining of epithelial cells only outside the nucleus. To evaluate the contribution of reuptake of extracellular IGFBP-5, T47D cells were incubated with Alexa Fluor 647-labeled IGFBP-5. The protein was taken up into intracellular vesicles and again was neither detectable in the cytoplasm outside of vesicular structures nor in the nucleus. Quantification of the time and concentration dependence of uptake by immunoblotting revealed that the process was saturable at IGFBP-5 concentrations between 1 and 2 mum and partially reversible with 30% remaining in the cell after a 1-h chase. The observation of nuclear uptake of IGFBP-5 was restricted to artificial conditions such as expression of non-secreted forms of IGFBP-5 or selective permeabilization of the plasma membrane by digitonin.
Collapse
Affiliation(s)
- Andreas Jurgeit
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
- Present address: Institute of Zoology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland
| | - Chiara Berlato
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Peter Obrist
- Department of Pathology, St. Vinzenz Hospital Zams, 6511 Zams, Austria
| | - Christian Ploner
- Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Petra Massoner
- Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
| | - Judith Schmölzer
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Michael C Haffner
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Helmut Klocker
- Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
| | - Lukas A Huber
- Division of Cell Biology, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Stephan Geley
- Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| | - Wolfgang Doppler
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Strasse 3, 6020 Innsbruck, Austria
| |
Collapse
|
46
|
Park JY, Park YH, Shin DH, Oh SH. Insulin-like growth factor binding protein (IGFBP)-mediated hair cell survival on the mouse utricle exposed to neomycin: the roles of IGFBP-4 and IGFBP-5. Acta Otolaryngol 2007:22-9. [PMID: 17882566 DOI: 10.1080/03655230701624822] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
CONCLUSION This study suggests for the first time that 1) IGF-I, IGFBP-4, and -5 alone and IGF-I+IGFBP-5 mixture stimulated hair cell survival and prevented neomycin-induced hair cell loss in the sensory epithelial culture of mouse utricles, 2) When administered together, IGFBP-4 diminished the effect of IGF-I, 3) In P3-5 mice utricle, IGF-I, IGFBP-4, and IGFBP-5 are expressed in the cytoplasm of hair cells. And Insulin/IGF-I Receptor is expressed in the nucleus of hair cells. OBJECTIVES Several growth factors have been demonstrated to protect auditory sensory cells in vitro and in vivo from aminoglycoside toxicity. IGF-I is one of the most well-known mitogenic and protective substance working in the inner ear. However, there are no reports available regarding the function of IGFBPs in the inner ear. In the present study, the effects of IGFBP-4 and -5 on hair cell survival were investigated in mouse utriclular organ cultures. MATERIALS AND METHODS The amount of cellular damage and cell viability in vestibular organs were assessed by counting hair cells stained with a rhodamine-phalloidin probe. The expressions of IGFBP-4, IGFBP-5, IGF-IR, and IGF-I were localized by immunohistochemistry. RESULTS When treated with IGF-I, IGFBP-4, or IGFBP-5 for 24 h, explant culture showed hair cell survival rates of 136+/-18%, 140+/-15%, and 133+/-6%, respectively, compared to controls. Neomycin (1 mM) induced hair cell loss resulted in 45+/-17% of hair cell survival. However, pre-treatment of IGF-I, IGFBP-4, or -5 before neomycin insult showed survival rates of 113+/-14%, 98+/-8%, and 73+/-24%, respectively. Similar to IGF-I, IGFBP-4 and IGFBP-5 were significantly protective. IGFBP-4 and -5 immunoreactivities were observed in the cytoplasm of normal explanted vestibular hair cells as well as in the P3 mouse utricular hair cells in vivo.
Collapse
Affiliation(s)
- Ji Yeong Park
- Department of Otorhinolaryngology, Seoul National University, Seoul, Korea
| | | | | | | |
Collapse
|
47
|
Baylink D, Lau KHW, Mohan S. The role of IGF system in the rise and fall in bone density with age. J Musculoskelet Neuronal Interact 2007; 7:304-305. [PMID: 18094484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Affiliation(s)
- D Baylink
- Department of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
| | | | | |
Collapse
|
48
|
Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, Kim JR. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007; 18:4543-52. [PMID: 17804819 PMCID: PMC2043568 DOI: 10.1091/mbc.e07-03-0280] [Citation(s) in RCA: 131] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The insulin-like growth factor (IGF) signaling pathway plays a crucial role in the regulation of cell growth, differentiation, apoptosis, and aging. IGF-binding proteins (IGFBPs) are important members of the IGF axis. IGFBP-5 is up-regulated during cellular senescence in human dermal fibroblasts and endothelial cells, but the function of IGFBP-5 in cellular senescence is unknown. Here we show that IGFBP-5 plays important roles in the regulation of cellular senescence. Knockdown of IGFBP-5 in old human umbilical endothelial cells (HUVECs) with IGFBP-5 micro-RNA lentivirus caused partial reduction of a variety of senescent phenotypes, such as changes in cell morphology, increases in cell proliferation, and decreases in senescence-associated beta-galactosidase (SA-beta-gal) staining. In addition, treatment with IGFBP-5 protein or up-regulation of IGFBP-5 in young cells accelerates cellular senescence, as confirmed by cell proliferation and SA-beta-gal staining. Premature senescence induced by IGFBP-5 up-regulation in young cells was rescued by knockdown of p53, but not by knockdown of p16. Furthermore, atherosclerotic arteries exhibited strong IGFBP-5-positive staining along intimal plaques. These results suggest that IGFBP-5 plays a role in the regulation of cellular senescence via a p53-dependent pathway and in aging-associated vascular diseases.
Collapse
Affiliation(s)
- Kwang Seok Kim
- *Department of Biochemistry and Molecular Biology
- Aging-associated Vascular Disease Research Center, and
- Department of Microbiology, College of Natural Science, Kyungpook National University, Daegu 702-701, Republic of Korea
| | - Young Bae Seu
- Department of Microbiology, College of Natural Science, Kyungpook National University, Daegu 702-701, Republic of Korea
| | - Suk-Hwan Baek
- *Department of Biochemistry and Molecular Biology
- Aging-associated Vascular Disease Research Center, and
| | - Mi Jin Kim
- Aging-associated Vascular Disease Research Center, and
- Department of Pathology, College of Medicine, Yeungnam University, Daegu 705-717, Republic of Korea; and
| | - Keuk Jun Kim
- Aging-associated Vascular Disease Research Center, and
- Department of Pathology, College of Medicine, Yeungnam University, Daegu 705-717, Republic of Korea; and
| | - Jung Hye Kim
- *Department of Biochemistry and Molecular Biology
| | - Jae-Ryong Kim
- *Department of Biochemistry and Molecular Biology
- Aging-associated Vascular Disease Research Center, and
| |
Collapse
|
49
|
Fleming JM, Brandimarto JA, Cohick WS. The mitogen-activated protein kinase pathway tonically inhibits both basal and IGF-I-stimulated IGF-binding protein-5 production in mammary epithelial cells. J Endocrinol 2007; 194:349-59. [PMID: 17641284 DOI: 10.1677/joe-06-0121] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The IGF system plays a key role in mammary gland growth and development. Our lab previously reported that IGF-I primarily regulates IGF-binding protein (BP)-3 in bovine mammary epithelial cells (MEC) and IGFBP-5 in mammary fibroblasts (MF). Presently, we examined the signaling pathways used by IGF-I to elicit this distinct, cell-type specific regulation. The phosphatidylinositol-3 kinase pathway was required for IGF-I to increase IGFBP-3 and -5 in MF and IGFBP-3 in MEC. Surprisingly, inhibiting the mitogen-activated protein kinase (MAPK) pathway in MEC increased IGFBP-5 mRNA levels 2- to 4-fold under basal conditions and 8- to 12-fold in cells treated with IGF-I within 4 h. Similar patterns of IGFBP-3 and -5 regulation were observed in murine MEC. Cells treated with IGF-I in the presence of MAPK inhibitors secreted more IGFBP-5 protein into conditioned media relative to cells treated with IGF-I alone; however, IGFBP-5 protein was not detected in conditioned media of cells treated with only a MAPK inhibitor. The IGFBP-5 mRNA response to MAPK inhibitors was specific for MEC, as blocking MAPK activity decreased the ability of IGF-I to induce IGFBP-5 in MF. In addition, no other IGFBP was increased in either cell type when MAPK activity was inhibited. These increases in IGFBP-5 expression in response to inhibition of the MAPK pathway corresponded with the induction of apoptosis. In conclusion, we report the novel observation that the MAPK/extracellular signal regulated kinase (ERK) pathway specifically represses IGFBP-5 expression in MEC. The corresponding changes in apoptosis and IGFBP-5 expression support a role for this specific IGFBP in mammary gland involution.
Collapse
Affiliation(s)
- Jodie M Fleming
- Rutgers, The State University of New Jersey, 59 Dudley Road, New Brunswick, NJ 08901-8520, USA
| | | | | |
Collapse
|
50
|
Abstract
The role of insulin-like growth factor binding protein 5 (IGFBP5) in tumorigenesis and development of cancer is not well-defined. IGFBP5 has been shown to either stimulate or inhibit cell proliferation via an IGF-dependent mechanism and to promote cell proliferation and migration in an IGF-independent manner. In the authors' previous study, IGFBP5 was found to be significantly up-regulated in lymph node metastases compared with their paired primary breast cancers. To further determine the role of IGFBP5 in breast cancer development and to evaluate its clinical significance in breast cancer, the mRNA expression level was detected in 30 normal breast tissues, 108 primary tumors, and 30 lymph node metastases using real time reverse transcription-polymerase chain reaction. The expression levels were correlated with several clinical parameters, including clinical stage, pathologic tumor size, axillary lymph node status, nuclear grade, estrogen receptor status, Her2 status, and local relapse or distant metastasis of the patients. As a result, the expression of IGFBP5 mRNA correlated positively with the invasion of axillary lymph nodes and the status of hormonal receptor. Furthermore, overexpression of IGFBP5 was associated with poor outcome of breast cancer patients with positive lymph nodes and negative ER. Thus, the expression level of IGFBP5 may contribute to the development of breast cancer and is a prognostic factor for breast cancer.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast/metabolism
- Breast/pathology
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/secondary
- Humans
- Insulin-Like Growth Factor Binding Protein 5/genetics
- Insulin-Like Growth Factor Binding Protein 5/metabolism
- Lymph Nodes/metabolism
- Lymph Nodes/pathology
- Lymphatic Metastasis
- Neoplasm Recurrence, Local/pathology
- Prognosis
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
Collapse
Affiliation(s)
- Xiaoqing Li
- Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
| | | | | | | | | |
Collapse
|